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AIM AND OUTLINE OF THE PhD PROJECT 
In the last few years there is a continuous research in the development of 
processes and techniques that allow to transform active pharmaceutical 
ingredients (APIs) into new dosage forms (Buttini, Colombo et al. 2012). The 
so-called “new drug delivery systems” are able to modify biopharmaceutical 
and pharmacokinetic properties of the API, to control its release rate, and to 
obtain a time specific delivery, reducing side effects. All these aspects may 
increase the therapeutic efficacy and the safety of both new and old drugs 
allowing an optimal use in clinical practice (Tiwari, R. et al. 2012). 
Particularly, in the field of modified release dosage forms, there has been a 
growing interest in time specific oral delivery, which generally refers to the 
pre-programmed release of drugs following administration to achieve 
improved therapeutic efficacy. These systems constitute a relatively new class 
of devices, the importance of which is especially connected with the recent 
advances in chronopharmacology (Roy and Shahiwala 2009; Bethke, 
Huennemeyer et al. 2010; Ohdo, Koyanagi et al. 2010). Chronopharmacology 
demonstrating the importance of biological rhythms in drug therapy, has led to 
a new approach to the development of drug delivery systems which are 
required to enable the drug release timing and control. In fact, treating diseases 
affected by the circadian rhythms, such as “early morning pathologies”, 
requires a desired concentration of drug available at expected times (Smith, 
Neutel et al. 2001; Ambedkar Sunil, Venkata Srikanth et al. 2013). This effect 
may be assured by device releasing no drug within the time gap and delivering 
the optimal amount at certain point correspondent to symptoms peak (Lemmer 
1991; Youan 2004; Lévi and Okyar 2011). Diseases with established circadian 
cycle show day-night patterns in the onset and symptoms exacerbation, usually 
with peaks in the morning and decrease throughout day. Moreover, the plasma 
concentration of C-reactive protein and interleukin-6 has been shown to follow 
a circadian rhythm in chronic inflammatory-based diseases such as rheumatoid 
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arthritis (Arvidson, Gudbjörnsson et al. 1994). The conventional treatment of 
these pathologies consists of daily administrations of non-steroidal or steroidal 
anti-inflammatory drugs (NSAIDs or SAIDs), which are often unable to 
coordinate drug release with clinical symptoms onset resulting in inefficient 
therapy and poor patient compliance.  
Moreover, as reported elsewhere, in the case of the management of chronic 
inflammation (rheumatoid arthritis) and associated pain, NSAIDs may be very 
effective if the drug is administered at least 4-6 hours before the pain reaches 
its peak (Gazzaniga, Palugan et al. 2008; Tavares, Wells et al. 2010). 
Therefore, many approaches have been used to design pharmaceutical dosage 
forms tailored to follow the human chronobiological rhythm (Hermida, Ayala 
et al. 2007; Smolensky and Peppas 2007; Lévi F and A. 2011) and, in the last 
few years, micro-technologies have been applied as innovative and efficient 
tool in drug delivery (Singh, Hemant et al. 2011) 
Several methods and techniques are potentially useful for the preparation of 
polymeric microparticles, such as spray drying, fluid bed coating, solvent 
evaporation, coacervation phase separation, prilling etc. The choice of a 
specific microencapsulation technology is related to the polymer nature, the 
chemical features of drug, the desired particles size as well as to the 
reproducibility and ease to scale ability of the method (Dalmoro, Barba et al. 
2012). 
In particular, design and production of hydrophilic mono- or multi-layered 
microparticles like hydrogel based beads thanks to their biocompatibility and 
ability to control drug release may be one of the most versatile strategies to 
produce chronotherapeutic drug delivery systems (ChDDS).  
The last decade has seen a shift from empirical formulation efforts to an 
engineering approach based on a better understanding of particle formation in 
the various microencapsulation techniques. The research group in 
Pharmaceutical Technology of the University of Salerno has developed  
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various advanced drug delivery systems that can dose orally, being less 
expensive and more compliant for the patients and at the same time extremely 
effective considering the specificity of early morning pathologies.  In 
particular, the group has acquired competence in particle design of polymeric 
hydrogel  microparticles (gel-beads) able to control rate, period of time and 
targeting of delivery. The processing method of choice is the relatively new 
and effective laminar jet break-up/prilling, using vibrating technology, which 
allows the  production of microparticles, in mild operative conditions, by 
breaking apart a laminar jet of polymer solution into a row of mono-sized 
drops under the influence of a superimposed vibration. The fall of the droplets 
into a polymer gelation solution produce solidified beads.  
Prilling has the capability to produce mono-dispersed, homogenous-shaped 
microparticles, with a narrow size distribution, using a short production time 
and it is easy to scale. However, particle engineering requires large 
experimental research into parameters that influence particle formation for a 
deeper understanding of particle formation process. 
In this context, this PhD project focused on the development by prilling of 
hydrogel based beads as controlled/delayed drug delivery systems for the 
chronotherapeutic treatment of rheumatoid arthritis with specific emphasis on 
the underlying particle formation mechanisms and design concepts. The beads 
were designed for a range of functions such as stabilization of the active, 
transport and targeting of the dose and mainly for release modulation 
achieving early morning pathologies requirements. Generally biodegradable 
and with excellent biocompatibility natural polymers are very attractive 
materials in microencapsulation and also are relatively inexpensive. 
Carbohydrate polymers, such as alginate and amidated low methoxyl (ALM) 
pectin were selected as polymeric carriers thanks to their ability to form 
hydrogels in mild operative conditions. It is well known that these polymers 
have gelling properties mainly due to the carboxyl groups able to engage in 
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coordination bonds with divalent cations forming a so called “egg-box” 
structure at ambient temperature. This property opens the possibility of 
encapsulating drugs, cells, proteins and other bioactive compounds under mild 
conditions, while maintaining their full biological activity. However, polymer 
type and its concentration, as well as cross-linking conditions are key 
parameters strongly affecting gelled microparticles performance. Therefore, 




), gelation times 
and gelling bath temperature on beads characteristics were investigated.  
Moreover, prilling process was deeply studied to optimize the final production 
conditions (polymeric solution flow, viscosity at nozzle, frequency and 
amplitude of the vibration, distance between the vibrating nozzle and the 
gelling bath), because of the many process and formulation variables that need 
to be tuned correctly to achieve the desired results, to link feed materials 
properties and process parameters to the resultant particle properties.  
Engineered beads were used as carrier for anti-inflammatory drugs with 
different chemical/pharmacological (NSAIDs or SAIDs) and pharmacokinetic 
characteristics (with short or long half-life), as well as different 
biopharmaceutical features in terms of solubility and permeability in 
accordance with the Biopharmaceutical Classification System (BCS). 
Particularly, the first part of the project was aimed to produce ChDDS loaded 
with ketoprofen and ketoprofen lysine salt as models of short half-life NSAIDs 
with different biopharmaceutical classification (Results Section A). Based on 
the acquired know-how, during the second part the research moved to the 
design and the development of ChDDS loaded with prednisolone as model 
SAID (Results Section B). The third part of the PhD project focused on the 
development of ChDDS containing piroxicam as model long half-life NSAID 
(Results Section C). 
According to the features of the selected drugs, different experiments were 
conducted in order to set the optimal formulation and prilling operative 
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conditions. In this way, gel-beads with proper morphological characteristics, 
good drug content (DC) and encapsulation efficiency (EE) values as well as 
controlled and delayed drug release profiles were produced. Formulations 
showing the best in vitro performances were selected as starting material for 
the preparation of more complex drug delivery technology platforms enabling 
an improved delayed delivery of the selected drugs. To design “smart” and 
efficient oral platforms for drug delivery, starting from comprehensive 
knowledge of the pharmacological and pharmaceutical properties of the drugs 
and polymers, different creative manufacturing processes were proposed:  
 Charge  of drug-carrying beads into specific DR® capsules to obtain final 
dosage form further delaying the drug release, 
 Core/shell microparticles consisting of a core (Zn-pectin ALM beads) and a 
gastro-resistant shell  formed by methacrylic acid - methyl methacrylate 
copolymer (Eudragit S100), 
 Floating beads which maximizing the gastric emptying process are able to 
prolong residence time in the stomach, obtained producing beads with 
specific excipients (gas-generating agent or low density/foaming polymers) 
able to confer floating ability to the final dosage form. 
All the platforms showed high effectiveness in sustaining the release over 
several hours and the potential to provide a viable alternative to conventional 
anti-inflammatory formulations. 
Moreover, the in vivo anti-inflammatory effect of optimized beads and 
platforms was studied using a modified protocol of carrageenan induced 
oedema in rat paw. The possibility to correlate the delayed and sustained drug 
release profiles evaluated in vitro  with in vivo performance (slow release of 
NSAIDs and SAIDs in rats) is essential in the pharmaceutical development in 














































1. Chronobiology and Chronotherapy 
The Chronobiology is the study of biological rhythms and their mechanisms 
and it’s clearly relevant in the fields of medicine, pharmacology, and drug 
delivery (Smolensky and Peppas 2007).  
Particularly, the term "chrono" basically refers to the study that every 
metabolic happening follows rhythmic changes in time (Surve, Sapakal et al. 
2013). Circadian rhythms (CRs) are, endogenous oscillations that occur with a 
periodicity of about 24 h and regulate many body functions like-metabolism, 
sleep pattern, hormone production etc. (Neeharika and Jyothi 2015) 
CRs are generated by suprachiasmatic nuclei located in the hypothalamus. 
This latter receives daily inputs from environmental cycles and generates 
rhythmic physiological outputs such as rest-activity, body temperature and 
hormonal secretions (Lévi and Okyar 2011). 
Several physiological processes in humans change in a rhythmic manner, in 
synchrony with the internal biological clock (Neeharika and Jyothi 2015). 
 
 





In addition to many biological functions, different diseases show rhythmic 
changes with time. Therefore, in view of this considerations based on 
chronobiology, in the recent years researches focus their attention on 
chronotherapy and chronopharmacology. 
Chronotherapy refers to a treatment method  in which in vivo drug availability 
is timed to match rhythms of disease in order to optimize therapeutic outcomes 
and minimize side effects (Surve, Sapakal et al. 2013). It’s based on the 
observation that there is a relationship between the peak of disease symptoms 
and risk factors, pharmacologic sensitivity and pharmacokinetic of many 
drugs. Chronopharmacology is a branch of chronotherapy that applies the 
principles of circadian rhythms to determine the best timing of drug 
administration, which can affect the absorption, distribution, metabolism, and 
excretion of administered substances (Ferrell and Chiang 2015). 
Chronotherapy does not only involve new medicines but uses also old ones in 
a  different approach. In fact, chronopharmacology evaluates person’s 
circadian rhythm in determining the timing and sometimes the right quantity 
of an active pharmaceutical ingredient (API)  to optimize the therapeutic 
efficacy and minimize undesirable side-effects.  
Hence, revising the dosing schedule, reformulating a drug in a suitable form, 
or using programmable dosage forms delivering an API at precise intervals, 
significant improvements could be achieved (Peppas and Leobandung 2004). 
1.1 Diseases affected by circadian rhythms  
Circadian disruption has been significantly linked to chronic jet lag and sleep 
disturbances and to increased incidence of cardiovascular events, 
gastrointestinal diseases, and metabolic syndrome. On the other hand, many 
chronic and acute disorders have a prominent circadian pattern of symptom 




Symptoms of asthma occur mainly in the night than during the day (Bohadana, 
Hannhart et al. 2002; Wagh and Kalshetti 2011). This effect is related to many 
circadian-dependent factors: for example cortisol levels are lowest in the 
middle of the night and histamine (a mediator of bronchoconstriction) 
liberation peak occurred at 4.00 am (Sajan, Cinu et al. 2009). 
Gastroesophageal reflux disease  
Gastroesophageal reflux disease that occurs during wakefulness is usually 
postprandial and rapidly cleared. Nocturnal gastroesophageal reflux events 
occur less frequently than during the daytime but are associated with longer 
acid clearance time due to sleep and/or circadian-related decreases in 
swallowing, saliva production, peristalsis (Orr, Allen et al. 1994; Litinski, 
Scheer et al. 2009). 
Alzheimer Disease 
Alzheimer disease (AD) affects about 15 million people worldwide, and is 
most commonly seen after age of 50, with progressive cognitive decline, 
circadian rhythm disturbances and sleep disturbances, including insomnia. 
“Sundowning” is a feature of AD, characterized by a late afternoon/evening 
predominance of activity, which some authors attribute to insufficient 
melatonin production (Cohen-Mansfield, Garfinkel et al. 2000; Hu, Van 
Someren et al. 2009).  
Epilepsy 
Epilepsy is another disorder that often exhibits a day/night variation in clinical 
presentation. Patients with epilepsy have seizures during the day only, or the 
night only, although some may have a more random pattern (Pavlova, Shea et 





Cardiovascular disorders exhibit differences in patterns of illness between day 
and night (Hermida, Ayala et al. 2007; Wagh and Kalshetti 2011). For 
example, there exists robust epidemiological evidence that the peak incidence 
of cardiac ischemic events, including angina, acute myocardial infarction and 
sudden cardiac death occurs around 9-11 am (Shea, Hilton et al. 2007; 
Litinski, Scheer et al. 2009). The peak incidence of the arrhythmias occurred 
between 10 and 11 am, with a nadir between 2 and 3 am. Arterial blood 
pressure (BP) generally falls during sleep and rises during activity, 
contributing to a day/night pattern in BP in most normotensive people as well 
as those with uncomplicated essential hypertension (Litinski, Scheer et al. 
2009). 
Cancer 
Epidemiological data indicate a link between various physiologic parameters 
having well-established day/night rhythms and carcinogenesis. For example, 
Rafnsson et al. found a higher rate of breast cancer in shift working and flight 
attendant females (Rafnsson, Tulinius et al. 2001). Severely disrupted 
rest/activity cycles in patients with metastatic colorectal cancer is 
accompanied by decreased survival compared with patients with a well-
preserved rest/activity pattern (Mormont, Waterhouse et al. 2000). 
1.2 Early morning pathologies (EMPs): Rheumatoid Arthritis 
The phrase "early morning pathologies" relates to pathologies, diseases, or 
other illnesses in which symptoms are typically more pronounced, aggravated 
or acute during the last hours of sleeping-time (4-6 am) or after the patient 
awakens from sleep (6-8 am) (Busetti and Crimella 2006).  
Between various disorders with pronounced early morning symptoms 
(ischemic heart diseases, arrhythmias, allergic rhinitis), this project focused on 
chronic inflammatory based diseases such as rheumatoid arthritis (RA). 
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RA is an autoimmune disease that is associated with progressive disability, 
systemic complications and early death. The cause of this pathology is 
unknown, and the prognosis is serious, the patient is acutely ill with a 
questionable outlook and a small chance for improvement. Rheumatoid 
arthritis is characterized by synovial inflammation and hyperplasia, 
autoantibody production, cartilage and bone destruction, and systemic 
complications, including cardiovascular, pulmonary, psychological, and 
skeletal disorders (McInnes and Schett 2011). 
Rheumatologists agree that RA patients show joint pain, morning stiffness, 
and functional disability in the early morning hours (Straub and Cutolo 2007; 
Gibbs and Ray 2013). This variation in symptoms expression is due to daily 
oscillations in plasma concentrations of hormones, disease-mediating 
cytokines, and other endogenous substances (Straub and Cutolo 2007; Perry, 
Kirwan et al. 2009). 
Hormones 
The differences in circadian rhythm fluctuations in healthy people compared 
to RA patients of some hormones have been studied. 
First of all, cortisol is the strongest endogenous anti-inflammatory substance 
and, in healthy subjects, its cycle shows a maximum in the early morning 
hours (8.00 am) and the lowest secretion point at midnight. This rhythm is 
highly disturbed in RA patients when the disease is very active with low 
cortisol levels at the early morning (Straub and Cutolo 2007). 
Besides cortisol two other hormones, melatonin and prolactin, exhibit a 
circadian rhythm. Both of them are correlated to stimulation of the immune 
system, that may lead to an increase in pro-inflammatory conditions in RA 
(Walker and Jacobson 2000; Maestroni, Sulli et al. 2002).  
The conventional circadian rhythm of melatonin and prolactin display a 
maximum at 3.00 am. Several researches revealed that in RA patients 
7 
 
melatonin and prolactin levels were significantly higher compared to normal 
subjects (Chikanza, Petrou et al. 1993; Sulli, Maestroni et al. 2002). This 
anomalous concentration induces a strong immune response and enhances 
inflammatory cytokine and nitric oxide production involved in immune and 
inflammatory response in RA at the early morning. 
Disease-mediating cytokines 
Cytokines like Tumor Necrosis Factor (TNF) and interleukin-6 (IL-6) exhibit 
a marked rhythmicity, in serum levels. In healthy subjects, the peak value of 
TNF is reached at ∼3:00 am and that of IL-6 at ∼6:00 am. In patients with 
RA, the peak level of TNF has been reported to appear at 6:00 am and that of 
IL-6 at 7:00 am (Straub and Cutolo 2007). 
For both cytokines, a time shift of the peak value toward the morning is 
observed. In healthy people, TNF and IL-6 levels are ∼2–5 pg/ml whereas in 
RA patients these levels are 20–50 pg/ml. In addition for  healthy people, 
serum levels of TNF and IL-6 have already begun to decrease at 6:00 am and 
9:00 am, respectively, whereas in RA patients these levels remain elevated 
until 10:00 am and 11:00 am, respectively (Straub and Cutolo 2007). 
Hence, there is a well-established up and down-regulation of cytokines (IL-6, 
TNF) and hormones that implicates fluctuations in immune and inflammatory 
response in RA. These data suggest that increasing levels of cytokines, 
melatonin and prolactin as well as inadequate low secretion of cortisol 
contribute to symptoms exacerbation in the early morning hours in patients 
with RA (Straub and Cutolo 2007). 
1.2.1 Conventional drugs used in RA treatment 
The main goals of RA therapy involve: stop inflammation, relieve symptoms, 
prevent joint and organ damage, improve physical function and overall well-
being, reduce long-term complications. 
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There are different drugs used in the treatment of rheumatoid arthritis. Some 
are used primarily to soothe RA symptoms and others are used to slow or stop 
the course of the disease and to inhibit structural damage. 
Disease-modifying antirheumatic drugs (DMARDs) target inflammation and 
reduce structural damage progression. Non-steroidal anti-inflammatory drugs 
(NSAIDs), reduce pain and stiffness and improve physical function, but do not 
interfere with joint damage and are thus not disease modifying. Steroidal anti-
inflammatory drugs (SAIDs) offer rapid symptomatic and disease-modifying 
effects but are associated with serious long-term side-effect (Smolen, Aletaha 
et al. 2016). 
DMARDs 
DMARDs represent the basis of pharmacologic treatment for RA (Clements 
2011). These drugs are classified on the basis of their “biologic” or “non-
biologic” activity.  
DMARDs therapy should be initiated within 3 months of RA diagnosis, 
allowing for aggressive treatment of the disease. Based on severity of the 
disease, particular DMARDs may be recommended and prescribed for an 
individual or specific patient. DMARDs without biologic activity include 
methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide. These 
agents do not target a specific component of the immune system involved in 
the pathophysiology of RA but have been shown to improve clinical 
outcomes. Later, thanks to an enhanced understanding in the pathophysiology 
of RA, more specific therapies (with biologic activity) have been developed to 
target a specific component of the immune system. DMARDs with biologic 
activity include TNF antagonists (etanercept, infliximab, adalimumab), IL 
antagonists (anakinra, tocilizumab), T-cell modulator (abatacept), and B-cell 




NSAIDs have been used in the management of RA for several decades. 
NSAIDs inhibit cyclooxygenase (COX) and prevent further formation of 
prostaglandins and other related inflammatory mediators. Based on their 
mechanism of action, NSAIDs are useful adjuvant therapy for the 
symptomatic management of RA, reducing joint swelling, tenderness, and 
pain. Most commonly used NSAIDs, include aspirin, diclofenac, ibuprofen, 
ketoprofen, piroxicam, sulindac and many others.  
The majority of these drugs are taken orally but, because of their short half-life 
need multiple daily administrations leading to toxicity and poor patient 
compliance. In fact, long term NSAIDs therapy includes several side effects 
such as gastrointestinal disorders, nephrotoxicity, anaemia and cardiovascular 
problems (Clements 2011).  
SAIDs 
SAIDs possess anti-inflammatory and immunosuppressive properties. Similar 
to NSAIDs, corticosteroids such as prednisone, prednisolone or 
methylprednisolone are commonly used for symptomatic management of RA. 
Corticosteroids may be used in combination therapy with DMARDs to avoid 
long-term adverse events. With long-term therapy, the lowest dose of 
corticosteroid is recommended to control symptoms and reduce the risk of 
adverse events (Clements 2011).  
Commonly, anti-inflammatory drugs (NSAIDs and SAIDs) employed to 
relieve symptoms, are administered to RA patient at different moments of the 
day (after awakening, after lunch, during the night) in immediate-release 
formulations. In this way, drugs are absorbed rapidly and explicate their action 
independently from the circadian rhythms of hormones and cytokines 
responsible of RA symptomatology. This conventional approach, usually leads 
to ineffective therapy because of drug liberation from the dosage form is not 
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synchronized with symptoms peak determining an increase of side effects and 
consequently poor patient compliance. 
1.3 Innovative oral treatments of RA: Chronotherapeutics  
In the last years some researches focused on the possibility to treat RA with a 
chronotherapeutic approach via oral route enhancing both patient compliance 
and therapeutic efficacy. 
Chronotherapy using glucocorticoids has achieved interesting outcomes. A 
modified-release tablet of prednisone has been developed able to release the 
drug ~4 hours after its ingestion; therefore, patients with RA do not need to 
take the drug during the night (2–3 am). A double-blind, randomised 
controlled trial showed that the prednisone modified-release tablet had better 
control of joint morning stiffness compared with the immediate release tablet 
(Buttgereit, Doering et al. 2008; To 2016). Moreover, studies of Alten et al. 
have demonstrated the safety and effectiveness of these tablets in that 
chronotherapy do not reduce hypothalamic–pituitary–adrenal axis function or 
the secretion of endogenous glucocorticoids (Alten, Döring et al. 2010; Alten, 
Holt et al. 2015). Therefore, chronotherapy using modified-release SAIDs 
formulations may be expected to become useful  in RA therapy . 
Moreover, the formulations of several available NSAIDs (ie, indomethacin, 
aceclofenac, ketoprofen, flurbiporfen, lornoxicam) have been recently 
modified, and some of them have been designed in order to obtain 
chronotherapeutic effects in RA (Cutolo 2016).  
Levi F. et al., found that an evening once daily scheduling of 75 mg 
(indomethacin formulation 25 mg immediate-release combined with 50 mg 
controlled-release) resulted in much greater control of morning symptoms 
compared to once-daily morning (breakfast time) or once-daily midday 
(lunchtime) schedules (Levi, Louarn et al. 1985). 
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A pH-responsive dual pulse multiparticulate dosage form containing 
ketoprofen was tested in RA and was found to be able to relieve circadian 
symptoms during midnight and early morning (Lotlikar, Kedar et al. 2010). 
2. Drug-delivery technology for chronotherapeutics  
The aim of Chronotherapeutic Drug Delivery System (ChDDS) is to 
synchronize drug delivery with circadian rhythms of a specific disease in order 
to optimize therapeutic efficacy and minimize side effects.  
An ideal ChDDS may be non-toxic, biocompatible and biodegradable, be easy 
to manufacture at economic cost and be easy to administer to patients in order 
to enhance compliance to dosage regimen (Devdhawala Mehul and Seth 
Avinash 2010). 
In particular advantages of ChDDS could be summarized as established by 
Neeharika and Jyonthi (Neeharika and Jyothi 2015): 
 Less inter-and intra-subject variability 
 Flexibility in design 
 Reduced frequency in dosage schedule 
 Improved bioavailability 
 Limited risk of local irritation 
 Unique release pattern 
 
Hence, a ChDDS must release the drug at predetermined rates and time to 
achieve optimal drug levels at the site of action when the therapeutic action is 
needed. Regarding RA, as previously reported, the symptoms exacerbation 
occurs at the early morning hours (4.00-6.00 am) therefore a ChDDS must 
release maximum anti-inflammatory  dose at this time. The optimal goal may 
be the production of oral controlled ChDDS releasing the maximum of the 




2.1 Oral controlled Drug Delivery Systems  
The oral administration is the most versatile, convenient and commonly 
employed route of drug delivery. Gastrointestinal physiology offers more 
flexibility in dosage form design than other routes, that is the reason why for 
controlled release systems, oral route of administration has received the most 
attention in developing controlled release systems (Tagde, Jain et al. 2012). 
Oral modified release delivery systems are most commonly used for: 
 Extended release,  
 Delayed release,  
 Pulsatile release;  
 Time or site specific release 
Oral programmed release (e.g., delayed, gastroretentive or time-specific 
release, etc.) and time-dependent delivery are main and primary aims of 
pharmaceutical technology research which would ideally enable the 
chronotherapy of various pathologies with night or early-morning symptoms 
such as RA (Maroni, Del Curto et al. 2012). 
Controlled release systems are based on polymers widely used in 
pharmaceutical dosage forms as release modifiers and release controllers of 
API via oral route. Depending upon the nature of polymer or a combination of 
polymers  used in formulations, they play an important role in inducing a 
delayed, and/or sustained, and/or time-specific drug delivery as well as in 
forming gastroretentive/floating formulations.  
Particularly, natural polymers resulted greater to the synthetic ones in respect 
of their highly organized macroscopic and molecular structure. This adds to 
their strength and biocompatibility. Moreover, their low toxicity and excellent 
biodegradability have also attracted researchers to pay attention towards the 
widespread application of natural polymers (Singh, Sharma et al. 2011). 
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2.2 Natural polysaccharides/carbohydrate polymers 
Natural polymers include proteins (collagen, albumin etc.) and 
polysaccharides or their derivatives. They are especially attractive because of 
their stability, availability, renewability and low toxicity. Moreover, the usual 
biocompatibility and biodegradability of these natural polymers, coupled with 
the possibility to tailor their physicochemical properties by chemical 
modification on the chain backbone structure, make them ideal excipients for 
the development of controlled drug release systems. 
From a chemical point of view, polysaccharide term includes different type of 
carbohydrates that can be composed of only one kind of repeating 
monosaccharide (homopolysaccharides) or made up by two or more different 
monomeric units (heteropolysaccharides) (Alvarez-Lorenzo, Blanco-
Fernandez et al. 2013). 
In nature, polysaccharides have various resources from algal origin (e.g. 
alginate), plant origin (e.g. pectin, guar gum), microbial origin (e.g. dextran, 
xanthan gum), and animal origin (chitosan, chondroitin). 
Furthermore, polysaccharides can be classified into polyelectrolytes and non- 
polyelectrolytes, the latter can be further divided into positively charged 
polysaccharides (as chitosan, polylysine, etc.) and negatively charged 
polysaccharides (alginates, hyaluronic acid, pectins, etc.) (Liu, Jiao et al. 
2008). 
2.2.1 Alginate 
Alginate, is a naturally occurring linear anionic polysaccharide extracted from 
brown seaweed, composed by β-D-mannuronic acid (M) and α-L-guluronic 
acid (G) residues linked by α-(1,4)-glycosidic bond. The blocks are composed 
of consecutive G residues (GGGGGG), consecutive M residues 
(MMMMMM), and alternating M and G residues (GMGMGM) (Fig. 2). 
Alginates extracted from different sources differ in M and G contents as well 
14 
 
as the length of each block, and more than 200 different alginates are currently 
being manufactured (Lee and Mooney 2012). 
. 
 
Figure. 2 Representative structure of alginate. 
Most of the commercially available alginates are in the form of the salt, that is, 
sodium alginate (SA). Sodium alginate is able to move from sol to gel state by 
ionotropic gelation under mild conditions through interactions between blocks 
of G residues and bivalent or trivalent cations resulting in the formation of an 
elastic hydrogel with good mechanical strength commonly referred as “egg-
box” model (Aquino, Auriemma et al. 2012).  
The chelation at the G-residue of the alginate molecules results in ionic 
interaction between the G groups while the van der Waal forces between 
alginate segments result in a three-dimensional gel network (Gaumann, 
Laudes et al. 2000). 
 


































suitable crosslinking agents (Chan, Jin et al. 2002) but not monovalent cations 
or Mg
2+
 (Goh, Heng et al. 2012). Literature survey confirms that calcium is the 
most used gelling agent to form alginate hydrogels (Agarwal, Narayana et al. 
2015; Zhang, Zhang et al. 2016). Ca
2+
 ions, preferentially interact with G units 
of alginate in a planar two-dimensional manner, while producing the so-called 
‘‘egg-box’’ structure (Goh, Heng et al. 2012). However, other divalent cations 
like Zn
2+
,  are less selective and interact with both G and M residues of 
alginate moieties producing more extensive cross-linking hydrogels (Chan, Jin 
et al. 2002) and seem to be more suitable for controlled drug delivery. 
Alginate hydrogels are useful as a matrix for cell immobilization, as well as 
entrapment of bioactive compounds and drugs for oral administration. These 
biomedical applications are mainly due to  pH-sensitive  characteristic of 
alginate beads (swells especially in neutral- and basic aqueous media, but sink 
in acidic aqueous solutions) able to protect drugs from environmental stress 
and from chemical/enzymatic digestion in gastric fluids  as well as to prolong 
the drug release, based on swelling properties.  
The material encapsulated within the inert alginate environment could be 
delivered at a desired rate in a controlled release system. Encapsulated drugs 
are released from alginate beads by diffusional processes through pores and 
the release is facilitated by the degradation of the polymeric network. In 
general, the release of water-soluble drugs is controlled predominantly by 
diffusion while that of water insoluble drugs is largely dependent on gel 
erosion (Goh, Heng et al. 2012).   
2.2.2 Pectin 
Pectin is a linear polysaccharide of α-linked anhydrogalacturonic acid with a 
certain degree of methyl esterification of carboxyl groups (Fig.4) (degree of 
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Figure 4. Representative structure of pectin. 
 
The most attractive property of pectin for industrial application is its gelling 
activity. Pectinate gel is water insoluble (water resistant), while still 
enzymatically degradable. For this reason, it can be used as an effective 
vehicle for drug delivery. Pectin can move from sol to gel state by thermal, 
acidic or cationic treatment. The choice of the pectin source as well as the 
gelation mechanism significantly influences the resulting gel nanostructure 
(Sriamornsak 2003). Indeed, the degree of esterification and the distribution of 
methoxyl-esters of each pectin type determine the main interactions between 
the polymer chains (hydrogen bonding, hydrophobic and ionic interactions) 
and the extent of chains alignment (Brejnholt 2009; García-González, Alnaief 
et al. 2011).  
Thermal treatment (heating) promotes the dissolution of pectin in water and, 
upon cooling below the so-called setting temperature, gelation takes place by 
hydrogen bonding between free carboxyl groups on the pectin molecules as 
well as the hydroxyl groups of the molecules. Acidic gelation promotes the 
hydrolysis of the methyl esters inducing a pectin structure predominantly 
composed of galacturonic acid (White, Budarin et al. 2009). Moreover, low 
methyl-esterified pectins require the presence of divalent cations for proper gel 
formation through ‘egg-box’ model mechanism by interaction of the cations 
(e.g., calcium, zinc, etc.) with galacturonic acid residues (Grant, Morris et al. 
1973; El-Nawawi and Heikal 1995; García-González, Alnaief et al. 2011). The 
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presence of sugar (10–20 wt.%) may also contribute to the decrease of 
shrinkage of the gel, as well as to confer firmness to the gel (García-González, 
Alnaief et al. 2011).Various reports suggest that Ca or Zn-pectinate systems 
may be viable carriers for controlled drug delivery to the colon due to 
digestion by specific enzymes produced by bacteria present exclusively in the 
colon. Unfortunately, their solubility and swelling ability in aqueous fluid 
cause premature drug release before the delivery system is able to reach the 
colon. First of all, this phenomenon can be controlled  through proper 
selection of pectin type and its concentrations, as well as gelation agent and 
cross-linking conditions (time, pH, conc. and nature of gelling solutions) 
(Sriamornsak and Nunthanid 1998; Das, Ng et al. 2010). Moreover, pectin 
beads could be used as starting material for the development of a final dosage 
forms through the combination with gastro-resistant excipients (Eudragit, 
cellulose acetate phthalate etc.) or through the insertion into specific capsules 
able to protect pectin beads from the acidic medium. 
2.3 Advantages and opportunities of polysaccharides-hydrogel based 
beads for the design of ChDDS 
Hydrogels are three-dimensional systems composed of hydrophilic polymers 
that can absorb water. They are not soluble in aqueous mixtures but swell due 
to the presence of chemical or physical crosslinks (Khan, Ullah et al. 2016). 
The degree of crosslinking, which is dependent on formulation conditions, is 
the most important factor affecting the properties of hydrogels. In fact, highly 
crosslinked hydrogels have a generally more compact structure and reduced 
dissolution rate and swelling ability. 
By controlling the swelling properties and other characteristics (solubility at 
different pH, mucoadhesion, etc.) in biological fluids, hydrogel based beads 
can be a useful tool for releasing drugs in a controlled manner at desired times 
18 
 
and sites as required for a chronotherapeutic system  (Smolensky and Peppas 
2007).  
Different microencapsulation techniques have been studied for the 
development of hydrogel based beads as carrier for drugs, peptides, proteins or 
for cells delivery. Many of these involve the use of organic solvents enhancing 
the possibility of adverse effects in the treatment of chronic diseases. For this 
reason, more interesting are biodegradable natural polysaccharides such as 
alginate,  pectin, chitosan which do not require organic solvents for the 
production of gel-beads and are potentially qualified for a number of chemical 
modifications (Patil, Kamalapur et al. 2010). 
One of the most common method used for the production of crosslinked beads 
is ionotropic gelation based on  the ability of polyelectrolyte polymers 
(alginate, pectin, chitosan, gellan gum) to cross-link in the presence of counter 
ions (Ahirrao, Gide et al. 2014).  
Generally, hydrogel beads are produced with a syringe, dropping the 
polymer/drug solution into a specific gelling medium (divalent cation, sodium 
tripolyphosphate) (Das, Ng et al. 2010; Mandal, Kumar et al. 2010; Vino, 
Paryani et al. 2012). However, the simple dripping method is often unable to 
produce beads with homogenous size and morphology resulting in poor 
process control and reproducibility. 
2.4 Prilling technique for the production of hydrogel based beads 
Prilling or laminar jet breakup is an emerging microencapsulation technique 
able to produce microparticles or beads with very narrow dimensional range 
and high encapsulation efficiency. It is a vibration-based technology 
consisting in breaking apart a laminar jet of polymer solution into a row of 
mono-sized drops by means of a vibrating nozzle device (Del Gaudio, Russo 
et al. 2009; Tran, Benoît et al. 2011). Once the droplets are formed, the 
gelation/consolidation step follows in order to prevent either the aggregation 
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of polymer droplets or the undesired leakage of encapsulated drugs. The 
chemical nature of the droplets (dispersed phase) determines the consolidation 
step, in which the droplets are transformed into solids microparticles known as 
gel-beads: this procedure can involve temperature modification, chemical 
reactions and mainly ionic cross-linking (ionotropic gelation). 
 
Figure 5. Vibrating nozzle device Nisco Encapsulator Unit, Var D. 
  
Several variables in prilling can affect droplet size and size distribution as 
polymer concentration and flow rate (Berkland, Kim et al. 2001; Mazzitelli, 
Tosi et al. 2008). Moreover, frequency of vibration as well as falling distance 
also affect particles characteristics, In fact, the longer the wavelength of the jet 
break-up, and the shorter the distance to the impact plane of the hardening 
solution, the less likely is drop coalescence. Thus, smaller nozzle diameters 
and higher frequencies increase the possibility of coalescence (Tran, Benoît et 
al. 2011). The frequency is usually kept as low as possible in order to avoid 
the formation of satellite droplets leading to a broader size range (Del Gaudio, 
Russo et al. 2009). 
The production of microparticles by the vibrating nozzle device is highly 
reproducible, time-saving, can be performed under aseptic and scaled-up 
conditions (Zvonar, Kristl et al. 2009). The acoustic jet excitation process 
involved in prilling was patented for production of uniform microspheres of 
alginate (Brandau 1995), collagen (Dumas, Tardy et al. 1992) and PLGA 
(Berkland, Pack et al. 2003b; Kim, Seo et al. 2008). The scale-up of the 
vibration process is easily done by using a multi-nozzle system (Fig. 6) 
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without changing other process parameters such as flow rate and the vibration 
frequency (Brandenberger and Widmer 1998). The most important element is 
about the arrangement of the nozzles which must ensure equal jet formation 
and equal pressure drops between the nozzles (Brandenberger and Widmer 
1998). The pilot apparatus using this technique is now being sold by Brace 
GnbH (Germany), Nisco Inc. (Switzerland) and Inotech AG (Switzerland) 
(Brandau 2002; Tran, Benoît et al. 2011).   
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SECTION A PART 1: 










Based on the article: A. Cerciello, G. Auriemma, S. Morello, A. Pinto, P. Del 
Gaudio, P. Russo, R.P. Aquino. “Design and In Vivo Anti-Inflammatory 
Effect of Ketoprofen Delayed Delivery Systems”, Journal of Pharmaceutical 
Sciences  2015 Feb; DOI 10.1002/jps.24554Epub 2015 Jun 18. 
26 
 
3-A 1.1 Scientific background and research aim 
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic 
and antipyretic properties indicated for the symptomatic treatment of pain and 
inflammation in osteoarthritis and rheumatoid arthritis. However, its efficacy 
is countered by a large number of side effects, especially those related to 
gastrointestinal complications. Moreover, its short biological half-life (t1/2 = 
2.1 h) and high frequency of dosing (2–4 times daily) increase health risks 
precluding a long-term use, as required in chronic inflammations and namely 
to relieve early morning pain in the management of osteoarticular pathologies 
(Arvidson, Gudbjörnsson et al. 1994). For these reasons, ketoprofen is a good 
candidate for the development of controlled release formulations, able to 
provide drug release at predetermined rate and time, targeting intestine, with 
the potential of reducing the well-known adverse effect of NSAIDs (Del 
Gaudio, Russo et al. 2009; Della Porta, Del Gaudio et al. 2013). 
Among different technologies proposed for the development of controlled and 
delayed drug delivery systems (Kamada, Hirayama et al. 2002; Stigliani, 
Aquino et al. 2013), prilling producing gel beads through vibrating nozzle 
extrusion was chosen as time-saving technique, offering several advantages 
compared with other microencapsulation technologies such as mild operative 
conditions (i.e., aqueous feed solutions, ambient temperature, and pressure) 
and an easy scale-up process (Del Gaudio, Colombo et al. 2005; Auriemma, 
Mencherini et al. 2013). 
In this work, a gel beads formulation was designed for delayed delivery of 
ketoprofen using alginate as a polymer carrier with emphasis on stabilization 
of the active, delivery and targeting of the API and mainly on drug  release 
modulation achieving early morning pathologies requirements that is to treat 
chronic inflammation and pain showing a circadian pattern with symptoms 
exacerbation in early morning (Lemmer 1991).  
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To achieve this goal, the main critical variables of the prilling process, i.e., 
composition of the aqueous feed solutions (sodium alginate and ketoprofen in 
different ratio), cross-linking conditions, frequency of vibration and flow rate, 
as well as beads micromeritics, were studied. In vitro dissolution/release 
performances were assessed in conditions simulating the gastrointestinal 
environment (USP 36). To demonstrate that delayed and sustained in vitro 
drug release profiles correlate with slow release  in vivo, the delayed anti-
inflammatory effectiveness was evaluated using a modified carrageenan-
induced acute oedema in rat paw (male Wistar rats) protocol. 
3-A 1.2 Gel-beads production and characterization 
Different experiments were conducted for the optimization of process 
parameters in order to obtain ketoprofen gel beads with desired size and high 
drug EE. Process parameters such as frequency of vibration and flow rate have 
been set according to Cross model equation to control the diameter of the 
drops coming out of the nozzle, producing hydrated beads with narrow size 
distribution (Aquino, Auriemma et al. 2012; Del Gaudio, Auriemma et al. 
2013). A 400 µm nozzle, frequency of vibration at 350 Hz (100% amplitude) 
and a feed flow rate of 5 mL/min were used; moreover composition of the 
aqueous feed solutions (e.g., polymer concentration and drug–polymer ratio) 
was also a critical parameter. As the successive ionotropic gelation of the 
formed droplets, behaviour of curing cross-linking divalent cations (Zn
2+
) by 
inducing ionotropic gelling of the polymer/drug drops, as well as pH of the 
gelling solution and cross-linking time were studied.  
This systematic study led to optimized operative conditions: sodium alginate 
of 2.0% (w/w), Zn
2+
 aqueous solution (10% w/v) as a gelling agent with 
gelling time around 2 min, and pH of the gelling solution set at 1.5. 
Particularly, Zn
2+ 
was selected as a cross-linker cation because its antioxidant 
properties may boost the efficacy of the anti-inflammatory drug encapsulated 
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in the polymeric matrix (Gaweł, Librowski et al. 2013; Abbas, Schaalan et al. 
2014). Formulations F5, F10, and F20 with different drug/polymer mass ratios 
(from 1:20 to 1:5, as shown in Table I) were obtained in a few minutes by 
prilling. As control, blank Zn–alginate beads (F) were produced too. The 
drying process of all the hydrated beads was conducted overnight by exposing 
hydrated beads to standard room conditions (22°C; 67% RH) for 12–18 h until 
constant weight was reached. 
 
Table I. Zn-Alginate-based beads loaded with K. Composition, theoretical and actual drug 
content, encapsulation efficiency, mean diameter and sphericity coefficient of Zn-alginate 

















F - - - - 2386 ± 119 0.93 ± 0.01 
F5 1:20 4.8 2.3 ± 0.2 48.2 ± 5.0 1813 ± 84 0.88 ± 0.02 
F10 1:10 9.1 4.3 ± 0.2 47.0 ± 1.9 1672 ± 52 0.91 ± 0.01 
F20 1:5 16.7 8.9 ± 0.2 53.0 ± 1.1 1770 ± 59 0.91 ± 0.01 
 
Analysis of the ADC and EE showed satisfying values for all dried 
formulations (EE ranging from 47% to 53%, as reported in Table I). However, 
it is interesting to point out that ADC and EE were related to the drug/polymer 
ratios. This result suggests that the loading of high amount of drug into feed 
solutions may promote, during the gelling phase, the formation of a more 
compact cross-linked matrix via intermolecular interactions, such as 
hydrophobic or hydrogen bonding, which stabilize the well-known “egg-box” 
structure (Lin and Metters 2006; Hoffman 2012). This phenomenon led to 
tough polymer beads and reduced the leaching of the drug from the drops into 
the gelling medium; accordingly, F20 formulated at the highest ketoprofen 
content (ketoprofen–alginate = 1:5) showed the highest entrapment of the drug 
within the matrix (EE = 53.0%). 
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With regard to the morphology, all ketoprofen-loaded beads exhibited a 
remarkable reduction in mean diameter in comparison to blank beads. In fact, 
F5, F10, and F20 displayed diameters in the range of 1672 µm (F10)–1813 
µm(F5), whereas F showed dimension greater than 2 mm (d = 2386 µm). 
 
 
Figure 7. Zn-Alginate-based beads loaded with K.SEM microphotographs of dried Zn-
alginate beads formulations: F (a), F5 (b), F10 (c) and F20 (d). 
 
Stabilization of the polymer matrix influenced beads shape after the drying 
process. In fact, SEM analyses confirmed that ketoprofen-loaded beads (both 
F10 and F20) had almost spherical shape, whereas F5 presented less regular 
contour with craters on the surface (Fig. 7). According to the ketoprofen 
loading, SC values were higher for drug-loaded beads value (>0.90), whereas 
F5 presented SC value around 0.88. Overall results from particle size and SC 
analysis suggest the formation of more compact cross-linked matrix according 
to the content of drug into the gel polymeric network.  
To better understand the influence of drug content on polymeric matrix 






Figure 8. Zn-Alginate-based beads loaded with K.SEM microphotographs at different 
magnifications of cryo-fractured beads: F10 (a-b) and F20 (c-d). 
 
Results from SEM showed that F20 had a more compact polymeric matrix 




Figure 9. Zn-Alginate-based beads loaded with K. Fluorescent microscopy images of K raw 
material (a), cryo-fractured blank Zn-alginate beads F (b), and cryo-fractured K loaded 
formulation F20 (c). 
 
Pure ketoprofen arose as a crystalline material with blue fluorescence 
consisting of small crystals (d50 = 3.1 µm) forming aggregates with large size 
(d50 = 20.5 µm) (Fig. 9a), while blank particles cross-sections (F) showed a 
pale yellow and off-white fluorescence (Fig. 9b). FM images of F20 (cryo-
fractured ketoprofen loaded beads) displayed fluorescent spots due to 
ketoprofen crystals homogeneously embedded within the Zn–alginate matrix 
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(Fig. 9c). As highlighted by FM images (Fig. 8), ketoprofen seems to keep its 
crystallinity after prilling and drying process, and crystal clusters of the drug 
were homogeneously embedded within the polymeric Zn–alginate matrix 
(Figs 8d and 9c). 
Moreover, to complete the technological characterization, DSC experiments 
on ketoprofen raw material and Zn– alginate beads, both blank (F) and 
ketoprofen loaded (F5–F20) were performed and the thermograms are shown 
in Figure 10. 
 
Figure 10. Zn-Alginate-based beads loaded with K. Differential scanning calorimetry 
thermograms of K raw material (a) and Zn-alginate beads, both blank F (b) and K loaded F5 
(c), F10 (d) and F20 (e). 
 
According to previous observations (Del Gaudio, Auriemma et al. 2013), 
thermal profile of crystalline ketoprofen raw material (Fig. 10a) exhibited a 
very narrow melting peak at 97°C with an intensity of −13.88 mW. The 
thermogram of blank beads F (Fig. 10b) showed two endothermic events, well 
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separated in temperature values, at 107°C and 190°C. The first event exhibited 
its onset at 84°C typical of the loss of hydration water from the polymer 
matrix (Pillay and Fassihi 1999; Atassi, Mao et al. 2010) and an intensity of 
−9.54 mW; the second event at 190°C was related to the endothermic melting 
process of the Zn–alginate matrix and had an intensity of −20.81 mW. This 
peak is followed by a ramp-like event ranging from 230°C to 252°C referable 
to polymeric matrix degradation. 
All ketoprofen-loaded beads (Figs. 10c–9e) showed a similar thermal trend 
with the endothermic events shifted at lower temperature. In fact, the first 
endothermic peak was found between 91°C and 94°C, for F5 and F20, 
respectively. The intensity of this peak increased with drug content and has 
been related to two simultaneous events overlapping in this range, namely, the 
loss of water and the melting of residual ketoprofen crystals, which were not 
encapsulated in the egg-box structure. The second endothermic melting 
process, between 155°C and 160°C, also showed an increased intensity related 
to ketoprofen content. Results suggest the establishing  of a physical 
interaction, which occurs between the polymer and the drug after loading into 
the polymeric matrix. 
Drug Release studies 
Pilot dissolution tests of all formulations were performed by conventional 
vessel methods (USP Apparatus 2, paddle) (Yang, Chu et al. 2002) using a 
classic pH change method, providing essential information and recommended 
in various guidelines (Rockville 1997) as a first choice for the in vitro 





Figure 11. Zn-Alginate-based beads loaded with K. Release profiles of K raw material (full 
triangle) and K loaded formulations F5 (empty circle), F10 (full square), F20 (empty 
diamond), performed by USP Apparatus 2 using a pH change assay. Mean ± SD; (n=6). 
 
Results showed that during the permanence of the formulations in acidic 
medium (2 h), F5 and F10 released 43.7% and 32.8% of the loaded 
ketoprofen, respectively. After the pH  change the drug release rate increased 
very rapidly, leading to a complete release of ketoprofen in simulated 
intestinal fluid (SIF) in about 1 h, whereas pure ketoprofen exhibited lower 
release rate (Fig. 11). Interestingly, ketoprofen release from F20 was greatly 
reduced (around 20%) in simulated gastric fluid (SGF) in 2 h. Thus, F20 acts 
as a gastro-resistant oral dosage form; complete drug release was achieved in 
SIF after pH change in about 1.5–2 h, with a dissolution rate lower than those 
observed for F5 and F10. 
Although previous papers reported no significant effects on drug release under 
simulated gastrointestinal environment by varying the ketoprofen 
concentration in Ca–alginate beads (Del Gaudio, Russo et al. 2009; Tous, 
Fathy et al. 2014), we observed that ketoprofen in vitro release rate from Zn–
alginate beads resulted strongly influenced by the amount of drug loaded. F20, 
formulated with the highest amount of ketoprofen, exhibited a gastro-resistant 
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profile followed by a slow and extended release of the drug in SIF (100% 
ketoprofen release at about 3.5 h, Fig. 11). These data matched with SEM 
microphotographs analyses of the cryo-fractured F20 beads (Figs. 8c and 8d). 
In fact, the loading of high amount of drug into feed solutions promote 
intermolecular interactions between the polymeric chains enhancing polymer 
entanglement during the gelling phase. This effect combined to the high cross-
linking degree due to zinc ions provides tougher polymer matrix, especially in 
F20, leading to a stronger resistance to drug diffusion.  
F20 dissolution behaviour was further investigated using the USP apparatus 4 
(flow-through, open-loop configuration), which is reported to closely mimic in 
vivo hydrodynamics and thus to better predict in vivo performance of solid oral 
dosage forms (Gao 2009; Fotaki 2011). 
 
Figure 12. Zn-Alginate-based beads loaded with K. Release profiles of F20 formulation, 
performed by USP Apparatus 2 (empty diamond) and USP Apparatus 4 (full diamond), using 
a pH change assay. Mean ± SD; (n=6). 
 
As shown in Figure 12, the apparatus 4 confirmed that F20 had enteric release 
behaviour (19% of the drug released in 2 h at pH 1) and in SIF showed a 
slower rate than that obtained using the USP paddle method. Differences 
between the two apparatus may be explained by the different hydrodynamic 
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conditions that characterize the flow-through cell system, where no agitation 
mechanisms occur and the dosage form is continuously exposed to a uniform 
laminar flow, similar to the natural environment of the gastrointestinal tract 
(Hu, Kyad et al. 2005; Medina, Salazar et al. 2014). 
F20 performance may be explained by considering the selected formulation 
factors  affecting the drug release and which can potentially influence oral 
absorption and bioavailability, namely alginate pH-dependent solubility, zinc 
cross-linking properties, and the obtained high structural density of matrix in 
F20.   
It is well known that drug release from alginate-based hydrogel beads depends 
upon the extent of crosslinking within the polymer, the polymeric composition 
and morphology,  the size and density of the beads, as well as the 
physicochemical properties of the incorporated drug. In-vitro drug release also 
depends upon pH and the used  dissolution media. The release of drug from 
these beads involves the:  
- desorption of the surface bound for the small amount of drug entrapped in 
the surface layer of the beads, 
- diffusion through the bead polymeric matrix which comprises three steps, 1) 
water penetrates into the polymeric system of beads causing swelling of the 
matrix. 2) the conversion of glassy polymer into rubbery matrix 3) the 
diffusion of drug from the swollen rubbery matrix, 
- bead polymeric matrix erosion  or -combined erosion /diffusion process. 
Our results indicated that F20 beads did not erode in SGF and still keep intact 
matrix, whereas in SIF (at pH 6.8) the main mechanism may be 
swelling/diffusion and successive erosion due to the ion exchange (Caballero, 





In Vivo experiments 
The anti-inflammatory activity of the formulation F20 in rats was evaluated by 
a carrageenan-induced oedema model and compared with the activity of pure 
drug. Rat paw oedema reached the maximum value (paw volume, mL) 
between 2 and 4 h after carrageenan injection, as shown in Figure 13. 
 
 
Figure 13. Zn-Alginate-based beads loaded with K. Dose-response curves of pure 
ketoprofen (1, 3 and 10 mg/kg doses) administered per os to rats 0.5h before carrageenan 
injection; mean ± SD (n=8). **P ≤ 0.01, ***P ≤ 0.001 compared with control. 
 
First, a dose–response curve of pure ketoprofen (1, 3, and 10 mg/kg per os 
doses) was performed following a conventional protocol, which prescribes 
drug administration 0.5 h before the injection of the phlogistic agent. As 
expected, the administration of pure ketoprofen caused a significant reduction 
of oedema after the first hour from carrageenan injection, compared with 
control at all tested doses. The anti-inflammatory effect of pure ketoprofen 
persisted even in the late phase of carrageenan induced rat paw oedema (24 h). 
These preliminary experiments suggest to select the dose of 3 mg/kg of 
ketoprofen as it achieved optimal anti-inflammatory effects (Fig. 13). 
With the aim to verify a potential delayed in vivo anti-inflammatory effect, 





















dose of 3 mg/kg) was administered orally following the same protocol at 
different time points (5, 3, or 0.5 h) before oedema induction.  
 
Figure 14. Zn-Alginate-based beads loaded with K. Oedema volume reduction obtained 
administering F20 and pure ketoprofen per os to rats 5 and 3h before carrageenan injection 
compared to control; mean ± SD (n=8). **P ≤ 0.01, ***P ≤ 0.001 compared with control. 
 
Interestingly, F20 showed a prolonged anti-inflammatory effect in terms of 
paw oedema inhibition after oral administration to rats compared with control. 
Pure ketoprofen (3 mg/kg) was efficient in reducing rat paw oedema only at t 
= 0 (0.5 h before phlogistic agent injection) (Fig. 13), whereas no response 
was observed when it was administered at 3 or 5 h before carrageenan 
injection. Blank Zn–alginate beads (F) did not significantly affect the paw 
oedema when administered to rats at the same time points before oedema 
induction (data not shown), thus, indicating that Zn–alginate matrix do not 
interfere with the inflammatory process. It is interesting to point out that F20 
administered 3 h or 5 h before oedema induction still showed a significant 
anti-inflammatory activity by reducing maximum paw volume (3–4 h) in 
response to carrageenan injection, therefore reflecting an in vivo delayed 
release (Fig. 14). 
The strong delay in drug anti-inflammatory activity appreciated in vivo may be 





















demonstrated in vitro and a further lowering of ketoprofen absorption in the 
GIT as an effect of the mucoadhesive properties of alginate beads (Aquino, 
Auriemma et al. 2013), which may guarantee a much more intimate and 
sustained contact with the absorption site (Moogooee, Ramezanzadeh et al. 
2011). 
3-A 1.3 Conclusions 
In many inflammatory-based pathologies, clinical symptoms are commonly 
most severe in the early morning, closely following the circadian rhythm of 
the pro-inflammatory mediators such as cytokines and interleukins. A delayed 
release dosage form administered prior to sleep and able to deliver NSAID 
several hours after oral administration may be optimally effective to treat early 
morning symptoms. 
The present study suggested that prilling by the accurate selection of 
biopolymers, the opportune set-up of process parameters and gelling 
conditions allows to produce interesting delayed drug delivery systems. 
Particularly, Zn
2+
 as gelling/curing cross-linker seems to affect 
physicochemical characteristics and in vivo performance of beads by a 
combination of effects. Technological properties of Zn–alginate-based beads, 
such as morphology, hardness of cross-linked matrix, mucoadhesion and, 
consequently, in vitro and in vivo release behaviour resulted strongly 
influenced by the amount of loaded ketoprofen. 
The optimized formulation F20 may be proposed as a chronotherapeutic 
system that is able to slow and delay in vivo ketoprofen release and absorption 
to 6–7 h. By opportunely timing the administration of the oral dosage form, it 
is possible to match the disease rhythms and to better control early morning 
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Based on the article: A. Cerciello, G. Auriemma, P. Del Gaudio, F. Sansone, 
R. P. Aquino, P .Russo. “A novel core–shell chronotherapeutic system for the 
oral administration of ketoprofen”. Journal of Drug Delivery Science and 
Technology, 2016, 32, 126-131. 
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3-A 2.1 Scientific background and research aim 
As reported in the part 1 of this section, ketoprofen may be encapsulated into a 
Zn-alginate matrix system with a quite satisfactory EE (higher than 50% for 
formulation F20). The Zn-alginate beads carrying ketoprofen resulted able to 
delay K release in vitro and prolong its anti-inflammatory effect up to 5h in 
vivo (Cerciello, Auriemma et al. 2015). 
Although results are quite good, beads overall performance leaves room for 
improvement both in the encapsulation efficiency of K and in a further delay 
of drug release.  
In order to further improve the beads loading capacity and the drug release rate 
control, a more complex drug delivery technology platforms was designed 
consisting of: 
 Core/shell microparticles made up by:  
 a core of a different natural biocompatible polymeric carrier (pectin-
based beads carrying ketoprofen)  
 and a gastro-resistant shell  formed by gastro-resistant methacrylic acid 
- methyl methacrylate copolymer. 
To achieve this goal, amidated low methoxyl (ALM) pectin was selected as 
alternative natural polysaccharide for the production of gel-bead core. 
ALM pectins ensure high hydrophobic interactions between pectin chains and 
additional internal hydrogen bonding between amide groups, thus, better 
stabilizing the egg-box structure (Auriemma, Mencherini et al. 2013). Zinc 
was selected as crosslinking agent; in fact, as reported in the literature zinc-
pectinate beads compared to calcium-pectinate beads are more able to resist in 
the upper gastro-intestinal tract and to refrain drug from premature release (El-
Gibaly 2002; Das, Ng et al. 2010; Dhalleine, Assifaoui et al. 2011). 
Considering that pectin usually exhibit poor stability in acidic conditions, the 
core-shell structure was designed  as a monolayer system (K-Zn-ALM-pectin 





). This synthetic polymer should protect the pectin-
based core from a premature acidic degradation thanks to its property to 
dissolve only at pH close to 7 (Dai, Guo et al. 2015). 
K-Zn-ALM-pectin core was produced by prilling deeply studying the process 
and formulation variables with special attention to ALM-pectin concentration, 
K/polymer ratio and gelling conditions (crosslinking agent concentration, pH 
and temperature) to optimize the production conditions and their effect on 
resultant particle properties (morphology, micromeritics, encapsulation 
efficiency) and performance (drug release).  
Beads micromeritics, as well as solid state characteristics were studied using 
established method (SEM, DSC). In vitro dissolution/release tests were 
assessed in conditions simulating the gastrointestinal environment (USP 36) 
by means of a pH change method.  
3-A 2.2 Pectin beads production and characterization 
Ketoprofen loaded gel beads with desired size and high drug EE were obtained 
using a ALM-pectin feed of 6.00% (w/w) in aqueous solution. Different 
amounts of ketoprofen were suspended into the polymer solution and stirred 
for 2 h in order to obtain 3 different drug/polymer ratios in the pectin solution 
(1:20, 1:10 and 1:5 w/w). Prilling operative conditions were set as for the 
production of alginate loaded K beads (Section1_Part1): 400 µm nozzle, 
frequency of vibration at 350 Hz (100% amplitude) and a feed flow rate of 5 
mL/min;  
The droplets produced by the laminar jet break up were collected into an 
aqueous solution of Zn (CH3COO)2×2H2O (10% w/v, pH= 1.5) where they 
were gelled under gentle stirring. The gelation time was maintained between 
5-10 min at room temperature then, the produced microparticles were 
recovered with a sieve and thoroughly rinsed with deionized water. Finally, 
the beads were dried at room temperature by exposure to air (22 °C; 67% RH) 
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for several hours (12-18 h) until constant weight was reached. In addition, 
blank beads of gel zinc pectinate (F) were produced as a control. 
The actual drug content (ADC) and encapsulation efficiency (EE) of dried 
beads were determined by UV-VIS spectroscopy and the results obtained are 
shown in table II.  
Table II. Zn-ALM-pectin-based beads loaded with K. Composition, theoretical drug 
content, actual drug content, encapsulation efficiency, mean diameter and sphericity 
coefficient of Zn-pectinate beads manufactured by prilling; blank (F) and loaded with 
ketoprofen (F20, F10 and F5). 
  
 
As reported in table II, also in the case of pectin based beads, ADC and EE 
were related to the drug/polymer ratio and EE increased with ADC increasing. 
This effect can be explained by assuming that the loading of larger quantity of 
K in the feed solution may promote the formation of a more compact 
polymeric matrix during the gelation process (Lin and Metters 2006; Hoffman 
2012). Hydrophobic interactions between the ketoprofen and the ALM-pectin 
are able to stabilize the egg-box structure reducing drug leaking from liquid 
drops to the gelling bath, and thus, allowing a best entrapment of ketoprofen. 
As a result, beads F5, formulated with the greatest amount of drug 















F - - - - 2.02 ± 0.08 0.91 ± 0.01 
F20
 1:20 4.8 3.9 ± 0.3 77.6 ± 2.6 2.51 ± 0.12 0.88 ± 0.04 
F10 1:10 9.1 7.4±0.3 81.3 ± 3.0 2.76 ± 0.12 0.89 ± 0.04 
F5 1:5 16.7 14.5 ± 0.3 86.7 ± 1.7 2.16 ± 0.10 0.99 ± 0.01 
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previously observed also for alginate based beads loaded with K suggesting 
that the drug and its amount play an important role in the gel matrix formation  
and the derived technological features (Cerciello, Auriemma et al. 2015).  
In order to study the main morphological characteristics of the produced gel 
beads formulations, SEM analyses combined to image J software elaboration 
were employed. Results revealed that K loaded microparticles have a mean 
diameter between 2.2 (F5) and 2.8 mm (F20), with F5 beads having highest 
sphericity coefficient (0.99). 
 
Figure 15. Zn-ALM-pectin-based beads loaded with K. SEM pictures of dried beads (left 
side) and of their surface (right side): F (a); F20 (b); F10 (c) and F5 (d). 
F5 resulted spherical in shape and showed an uniform surface (Figure 15), 
while beads F (control blank), F20 and F10 (Fig. 15 a-c) presented a less 
regular geometry. The morphology  results confirm that the loading of larger 
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amount actively contributes to the formation of a high structural density  
matrix, able to give to gel beads a well-defined morphology. Moreover, as 
evidenced by higher magnification photographs (Fig. 15, right side), showing 
the distribution of drug crystals on the surface of beads, F5 showed the lowest 
quantity of ketoprofen crystals on the surface (Fig. 15 d’), confirming the 
highest encapsulation efficiency. 
With the aim to study the solid state of the drug before and after the 
encapsulation process and to highlight potential drug-polymer interactions, a 
series DSC experiments were performed  (on ketoprofen raw material, on 
developed formulations and on blank beads (F) as control). 
 
Figure 16. Zn-ALM-pectin-based beads loaded with K. DSC thermograms of: ketoprofen 




As reported in figure 16, ketoprofen raw material shows the typical thermal 
profile of a crystalline compound, with a melting peak at 98 °C (Auriemma, 
Del Gaudio et al. 2011). The thermogram of F beads (Fig 16b) shows two 
endothermic events in the range of 90 -120 °C and at 170 °C. The first signal 
corresponds to the loss of water adsorbed on the surface and entrapped into the 
gel matrix (Pillay and Fassihi 1999),  the second at 170° C is due to the 
melting of zinc pectinate matrix. These events are followed by an exothermic 
signal ranging from 200 °C to 250 °C with a ramp-like trend, attributable to 
the degradation of cross-linked matrix. Drug loaded beads, F20 and F10, 
obtained with 1:20 and 1:10 drug/polymer ratio exhibit a thermal behaviour 
comparable to F beads (Fig. 15 c-d). The thermogram of F5 (Fig 16e), with the 
highest drug content, shows the melting endothermic peak of zinc pectinate 
slightly shifted at lower temperatures (155 °C vs 170 °C). This behaviour may 
be due to physical interactions between the polymer and the encapsulated drug 
(Liu and Guo 2006), Moreover, drug charged beads showed the melting peak 
of ketoprofen shifted at lower temperatures related to the presence of aliquots 
of drug embedded into the matrix and close to the surface.  
Drug release studies 
In order to have an indicator of performance, in vitro drug release assessment 
was carried out evaluating ketoprofen dissolution profile from ALM-pectin 
formulations, through a USP apparatus II using a classic pH change method (2 
h in 0.1 M HCl, and then in 0.2 M of Na3PO4 at pH 6.8). The dissolution 





Figure 17. Zn-ALM-pectin-based beads loaded with K. Drug Release profiles of pectin 
based beads F20 (), F10 () and F5 () compared to K raw material () . 
 
Results demonstrated that the beads drug content may affect the amount of 
drug released especially in SGF. In fact, #F5, formulated with the greatest 
amount of ketoprofen, released into the gastric simulated fluid only 22.2% of 
the loaded drug and reached the complete release of the drug in SIF after 1 
hour from pH change. The lower percentage of drug released in gastric 
environment from F5 compared to F10 and F20 was related, firstly, to the 
lower quantity of drug crystals on beads surface as evidenced by SEM 
photographs (Fig. 15). Moreover, this result supported the hypothesis that the 
loading of higher amounts of drug contributes to produce a tougher polymeric 
matrix able to better encapsulate the drug during the ionotropic gelation 
process as well as to retain the drug when it is in contact with biological fluids. 
The tough polymeric matrix also deriving from the high degree of crosslinking 
caused by zinc ion, increased the structural density of the F5 polymeric matrix 
after drying process, contributing to delay the release of ketoprofen. After 
changing the pH,  a rapid swelling and erosion process in SIF takes place, 
pectin chains are hydrolysed and complete the drug release in about 1 hour; 
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the phosphate ions in simulated intestinal fluid (SIF) determined, in fact, the 
capture of zinc ions from the cross-linked polymeric matrix, causing its 
dissolution with consequent prompt release of the encapsulated drug. 
Design and production of core-shell microparticles  
Considering the rapid swelling and  erosion process in SIF, monolayer pectin 
based beads are able to delay K release only up to 180 min and, this lag time, 
was inadequate for a chronotherapeutic treatment of RA, whereby, beads were 
coated with Eudragit S100
®
, an anionic copolymer of methacrylic acid and 
methyl methacrylate insoluble in acid pH (de Arce Velasquez, Ferreira et al. 
2014; Maghsoodi 2014; Dai, Guo et al. 2015), to obtain core-shell system. 
 
Figure 18. Zn-ALM-pectin-based beads loaded with K. SEM picture of cryo-fractured 
(F5)-shell (40% w/w Eudragit S100
®
) system, with magnification of the core-shell structure. 
 
In preliminary experiments, the covering level of F5 beads was varied between 
10 and 60% w/w. A uniform coating of about 100 µm was achieved with the 
addition of 40% w/w of enteric polymer, as shown in figure 18, while with a 
20% w/w Eudragit S100
®
 content the shell cannot cover the entire particles 
surface and a 60%w/w of Eudragit S100
®
 produced adhesive particles that 
tended to aggregate. 
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The  in vitro dissolution performance of final technological platforms 
F5/ES100 is reported in figure 19. 
 
Figure 19. Zn-ALM-pectin-based beads loaded with K. Drug Release profiles of core shell 
microparticles F5/ES100 () compared to monolayer formulation F5 (). 
 
 
Interestingly, the core (F5)-shell (40% w/w Eudragit S100
®
) system showed a 
strong delay of ketoprofen release in SGF followed by a slow and controlled 
release in SIF. The core-shell system is able to significantly reduce the release 
of ketoprofen in acid pH from 22.2% (monolayer F5) up to 7.3% and extend 
its release in simulated intestinal environment. After the pH change, in fact, 
the drug release was completed in about three hours (t = 300 min) rather than 
in one hour (t = 180) as for F5. 
Only after the dissolution of the Eudragit S100
®
 shell in SIF, the pectin/drug 
core was exposed to the fluid and pectin chains started later the hydrolysis 
process, releasing slowly the encapsulated drug. 
 
3-A 2.3 Conclusions 
The present study suggested that prilling may produce core-beads of pectin 
showing narrow size distribution and high drug content and encapsulation 
efficiency. ALM-pectin beads opportunely gelled with Zn ions revealed as an 
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alternative polymeric carrier to alginate for ketoprofen oral delivery. In 
particular, the loading of larger amounts of drug in the feed solution (1:5 
drug/polymer ratio as in F5) may promote, as previously observed for Zn-
alginate beads, the formation of a compact cross-linked matrix, allowing high 
encapsulation efficiency (87%) and reducing drug release in simulated gastric 
fluid (22%). The core-shell system may be obtained applying a gastro-resistant 
polymer, Eudragit S100
® 
as a shell (40% w/w) to F5 core. The core-shell 
system developed was able to dramatically increase the retain of ketoprofen in 
the acid simulated environment (7.3% drug released in SGF) and to prolong 
the release in simulated intestinal environment until 5 h. This optimized 
technology platform appears, therefore, feasible and potentially effective as a 
dosage form suitable for the chronotherapy of RA. The control and strong 
delay in the NSAID release suggests a drug products to be taken at bed time 
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Based on the article: A. Cerciello, G. Auriemma, P. Del Gaudio, M. 
Cantarini, R.P. Aquino. “Natural polysaccharides platforms for oral controlled 
release of ketoprofen lysine salt”,  Drug development and industrial 
pharmacy, 2016, dx.doi.org/10.1080/03639045.2016.1195401. 
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3-A 3.1 Scientific background and aim 
In the first part of my PhD project (Section A, part 1-2), the work was aimed 
to encapsulate a poor soluble NSAID, ketoprofen K (BCS class II), optimizing 
formulation and operative conditions of prilling technique accordingly to the 
physic-chemical characteristics of the selected drug. 
In this part of the PhD program, the versatility of prilling technique for the 
production of engineered microparticles was evaluated loading an highly 
soluble NSAIDs Ketoprofen lysinate (KL), using Zn-alginate and Zn-ALM-
pectin as release controllers. 
Particularly, KL, the water soluble lysine salt of ketoprofen (K), is commonly 
used in the symptomatic treatment of various chronic inflammatory diseases 
such as RA (Gentile, Boltri et al. 1999) and it is frequently used in paediatric 
therapy for its analgesic efficacy.  
Furthermore, compared to K, L-lysine salt has shown better pharmacokinetics 
and tolerability, enhancement in the rate of absorption, reduction of the onset 
of therapeutic effect as well as improvement of the gastric tolerance (Cimini, 
Brandolini et al. 2015).  
Although several studies have been reported on polysaccharide hydrogels 
entrapping the non-soluble form of K (Del Gaudio, Russo et al. 2009; 
Prajapati, Patel et al. 2012; Cerciello, Auriemma et al. 2015), few or no 
researches are available on L-lysine salt. In fact, the high KL solubility is the 
limiting step for the formulation of delivery systems with high drug 
encapsulation efficiency and, above all, controlled release properties. 
To achieve this goal, many formulation and prilling process variables have 
been investigated to find the optimal ones. Moreover, due to the high KL 
solubility in simulated biological fluids, the optimized formulation was 
selected as starting material for the preparation of an advanced delivery 
platform charging drug loaded beads in specific acid-resistant capsules. A 
similar platform may be potentially able to guarantee a delayed and sustained 
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drug release. Different types of capsules were taken into account and finally 
DR
®
 capsules were selected as the proper ones (Cerciello, Auriemma et al. 
2016). 
3-A 3.2 Gel-beads production and characterization 
Two series of KL hydrogel-based beads were prepared by prilling using 
alginate or ALM-pectin as carrier material.  
All beads formulations were prepared using Zn
 
as gelling agent and optimizing 
cross-linking conditions in terms of temperature (4-5 °C), pH (1.5) and gelling 
time (2 min) in order to limit drug leaking during the ionotropic process 
accordingly to the high KL solubility. In fact, as reported elsewhere, 
temperature as well as pH are key parameters to properly set (Sriamornsak 
2003) in order to improve the gelling properties of pectin or alginate and, 
consequently, limit drug leaking typical of high solubility API. In fact, as 
reported for pectin beads, at high temperature (or pH increase), a chain 
cleavage process starts and results in very rapid loss of viscosity and gelling 
properties (Sriamornsak 2003). In addition the gelling time was maintained as 
low as possible to obtain a compact hydrogel reducing the potential drug 
leaking. 
Six formulations, namely F2-F8, as shown in Table III, were produced using 
2.0% and 6.0% w/w polymer concentrations for alginate or pectin, 
respectively, and varying drug-polymer ratio from 1:20 to 1:5. As control, 
blank beads (F1, alginate and F5, pectin) were also produced. Drying process 
of the hydrated beads was conducted by exposing beads to standard room 
conditions (22 °C; 67% RH) for 12–18 h until constant weight was reached. 
Results reported in Table III showed that actual drug content (ADC) and 
encapsulation efficiency (EE) values were related to the specific polymeric 
material used to manufacture the beads and drug polymer ratio. The higher the 
drug polymer ratio, the higher the EE. KL encapsulation process was more 
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efficient in pectin than in alginate with EE values ranging from 39.0% to 
49.7% for zinc-alginate beads (F2, F3, F4) and from 81.8% to 93.5% for 
pectin-based beads (F6, F7, F8), probably due to pectin lower molecular 
weight that enhanced gel matrix texture (Mesbahi, Jamalian et al. 2005; Kim, 
Kim et al. 2010). 
Table III. Zn-alginate and Zn-ALM-pectin-based beads loaded with KL. Formulation 
code, polymeric carrier, actual drug content (ADC), encapsulation efficiency (EE), mean 




















- - - 2386 ± 119 0.93±0.01 
F2
 1:20 1.9±0.1 39.0±1.6 2456 ± 88 0.91±0.01 
F3 1:10 4.1±0.5 44.8±2.7 2210 ± 97 0.89±0.02 




- - - 2002 ± 80 0.91±0.01 
F6 1:20 3.9±0.2 81.8±4.0 2119 ± 112 0.85±0.05 




93.5±2.9 2200 ± 134 0.91±0.01 
 
To better understand the influence of the specific polymer on gel-matrix 
texture, beads were cryo-fractured and analysed by SEM. Results highlighted 
a homogeneous and tougher inner matrix for pectin based beads compared to 
those produced with alginate.  
 
Figure 20. Zn-alginate and Zn-ALM-pectin-based beads loaded with KL. SEM 




In fact, as shown in Figure 20, KL crystals were homogeneously embedded 
within the Zn-ALM-pectinate matrix (Fig. 20-b) whereas they spread out on 
the surface for all Zn-alginate beads (Fig. 20-a). It can be assumed that this 
effect is due to the formation of several intermolecular hydrogen bonds and 
hydrophobic interactions between KL and pectin amino residues able to 
deeply stabilize the egg-box structure (Liu, Fishman et al. 2005; Sato and 
Miyawaki 2008). During the cross-linking phase, high density of the formed 
hydrogels can reduce the drug leaking from the hydrated beads to the gelling 
bath, allowing high KL entrapment (Hoffman 2002; Lin and Metters 2006). 
Moreover, the strong hydrogel network can determine a high shrinkage of the 
volume after drying process, leading to a significant reduction in mean 
diameter of the beads. In fact, ALM-pectin-based beads showed lower size 
than alginate based beads with reduction in mean diameter of 45% and 23%, 
respectively.  
As pointed out by SEM analyses combined to image J software elaboration 
(Table III), mean diameters ranged from 2002 to 2200 µm for zinc-pectinate 
beads while zinc-alginate beads showed mean diameters between 2210 and 
2456 µm. On the contrary, no significant differences were observed in terms 
of shape and sphericity coefficient among pectin or alginate based beads as in 
terms of KL polymer ratio.  
SEM analyses at higher magnification showed that all KL alginate beads (F2-
F3-F4) exhibited on the surface micrometric KL crystals; the amount of such 
crystals was not dependent on the drug-polymer ratio used to formulate the 




Figure 21. Zn-alginate and Zn-ALM-pectin-based beads loaded with KL. SEM 
microphotographs at different magnification of dried Zn-alginate beads: F2 (a–d), F3 (b–e) 
and F4 (c–f). 
 
This phenomenon may be due to the incapability of zinc-alginate gel network 
to retain into its texture a highly soluble drug like KL that, during drying 
process migrates on the surface of the beads. On the contrary, analysing KL 
pectin-based beads, the presence of drug crystals was strictly related to KL 
content.  
In fact, as shown in Figure 22, F6 showed only tiny spots of the drug on beads 
surface whereas in case of F7 and F8, in spite of a tougher polymeric matrix, 
drug loading enhanced KL diffusion on beads surface. 
 
 
Figure 22. Zn-alginate and Zn-ALM-pectin-based beads loaded with KL. SEM 




In order to study the effect of prilling process on the encapsulated drug as well 
as potential KL-polymers interactions, differential scanning calorimetric 
technique was used. In fact, DSC analysis is a well-known method often used 
to characterize physical and chemical changes in either enthalpy or heat 
capacity of a crystalline drug in a polymeric matrix after the encapsulation 
process (Manjanna, Rajesh et al. 2013). DSC thermal profiles of KL raw 




Figure 23. Zn-alginate and Zn-ALM-pectin-based beads loaded with KL. Differential 
scanning calorimetry thermograms: KL raw material (a) and blank Zn-alginate beads (b), F4 
(c), blank Zn-pectin beads (d) and F8 (e). 
 
KL exhibited the typical profile of a pure crystalline drug with a melting peak 
at 170°C. Thermograms of blank Zn
2+
-alginate beads (F1) showed two 
endothermic events, well separated in temperature values, at 107°C, 
corresponding to the loss of hydration water from the polymeric matrix (Pillay 
and Fassihi 1999; Cerciello, Auriemma et al. 2015); and at 190°C, 
corresponding to the melting of zinc-alginate matrix. These events are 
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followed by a ramp-like event ranging from 220°C to 300°C referable to 
cross-linked matrix degradation. KL loaded alginate beads, as reported for F4 
(Figure 23-c), showed a thermal trend comparable to F1 beads. However, the 
first broad endotherm ranging from 90 to 115°C showed a higher peak 
intensity due to the increased water content, whereas the second endothermic 
peak resulted shifted at lower temperature. The last effect may be due to the 
presence of KL on the beads surface into the matrix as shown by SEM images 
and it is more evident in F4 beads formulated with the highest KL amount 
(drug/polymer ratio 1:5). Regarding ALM-pectin-based formulations, blank 
beads F5 showed an endothermic event at 145°C due to the melting of the zinc 
pectinate matrix and an exothermic signal at 165-220°C due to its degradation. 
Thermal profile of F8 (Figure 23-e), reported as example, exhibited significant 
shifts of these events at higher temperatures (160-180°C and 240°C), which 
may be attributed both to drug polymer matrix interaction and to a slower heat 
transfer correlated to the increase in beads hardness (Pawar, Gadhe et al. 
2008). 
Drug release studies 
To verify whether the produced polysaccharides-based beads can be carriers 
able to modulate KL release in the gastrointestinal tract, dissolution tests were 
performed by means of the USP Apparatus II (Yang, Chu et al. 2002), using a 





Figure 24. Zn-alginate and Zn-ALM-pectin-based beads loaded with KL. KL release 
profiles of formulations F4, F6, F7 and F8, compared to KL raw material. 
 
All alginate based beads provided fast and complete drug release in acidic 
medium, without any lag time, in 120 min. Formulation F4, reported as 
example, released total KL dose at the end of the acid cycle.  
On the contrary, all pectin based beads were able to achieve KL sustained 
release. In fact, during the permanence in acidic medium (120 min) the 
cumulative percent drug release was 56.2%, 39.1% and 31.9%, for F6, F7 and 
F8, respectively. After the pH change, drug release rate increased very rapidly, 
leading to KL complete delivery in about 1 h (t=180 min).  
The specific drug release profile from each formulations’ series perfectly 
matches with beads morphology and structure data obtained by SEM 
investigation. The F4 faster release in gastric environment was due to the 
presence of KL crystals on beads surface as well inside inner polymer matrix 
texture, which makes them highly permeable. On the contrary, the release 
performance of Zn
2+
-ALM-pectinate beads can be related to their structural 
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density which reduces swelling and erosion processes in SGF, keeping the 
xerogel matrix intact (Pal, Singh et al. 2013; Cerciello, Auriemma et al. 2016).  
Interestingly, results also showed that the amount of KL released in acidic 
medium decreases with drug content. Therefore, the loading of large amounts 
of KL in pectin based beads may promote, during the gelling phase, the 
formations of additional intermolecular interactions between polymer chains 
and KL, as also pointed out by DSC analyses, able to further stabilize the final 
xerogel matrix. These results are consistent with recent literature studies, 
confirming the higher suitability of LMP to produce xerogel beads with 
improved technological properties if compared to alginate (Voo, Ravindra et 
al. 2011; Belscak-Cvitanovic, Komes et al. 2015). 
As initially planning for an highly soluble API, with the aim to further limit 
and delay KL release performances, F8, the most promising formulation, was 
selected as starting material for the preparation of a drug delivery platform 
made up by DR
®
 capsules and F8 (F8/DR caps). Differently from 
conventional gelatin capsules that undergo breakdown in simulated gastric 
fluid in about 5 minutes, the DR
®
 caps begin to disaggregate after 75-90 
minutes enabling the protection of F8 formulation from the acidic 
environment. 
 
Figure 25. Zn-alginate and Zn-ALM-pectin-based beads loaded with KL. KL release 




As reported in Figure 25, F8/DR caps platform showed a strong delay of KL 
release in acidic environment followed by a slower release in SIF. In fact, 
F8/DR caps platform is a gastro-resistant formulation, reducing KL release in 
SGF from 31.9 to 8.8%, and prolonging its release in intestinal simulated fluid 
until 270 min compared to 180 min as observed for F8. Only after the 
disaggregation of the capsule’s body, beads came into contact with the 
dissolution medium, starting later the dissolution process. After a lag time of 
about 90 min, beads are released from the capsule, start to hydrate and swell 
allowing a slight drug diffusion in acid medium followed by slower 
swelling/erosion processes in intestinal simulate fluid. 
Drug release rate from the optimized platforms (ALM-pectin xerogel beads 
plus DR® capsules) may be potentially useful for the targeted release of BCS 
class I drugs, such as KL and theophylline, BCS class II drugs, as 
indomethacin, or even macromolecules, such as BSA, improving in all cases 
bioavailability of the loaded active pharmaceutical ingredient. 
3-A 3.3 Conclusions  
The present study suggests that prilling technique, conveniently optimized in 
terms of composition of feed solution, process parameters and gelling 
conditions, can be successfully used to encapsulate highly soluble drugs such 
as KL in polysaccharides-based hydrogels. ALM-pectin proved to be a proper 
polymer able to encapsulate ketoprofen lysine salt. F8 formulation was 
produced using 6% w/v polymer feed, drug-polymer ratio (1:5) and 10% w/v 
of zinc acetate (T= 4-5˚C, pH= 1.5, 2 min) gelling conditions. Xerogel beads 
showed good morphological and size properties, high drug content and 
encapsulation efficiency and, finally, interesting drug release profiles. Hosting 
F8 in appropriate acid-resistant capsules such as DR® caps a new delivery 
platform has been obtained able to control KL release in a delayed (90 min lag 
time) and prolonged (270 min for complete delivery) way. The platform may 
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be proposed as potentially useful in the administration of highly soluble 






































Design and development of ChDDS 














Scientific background and general aim 
The first part of my PhD project, as reported in section A, was aimed to 
produce NSAIDs delivery systems  (monolayer gel-bead and core-shell 
particles) with high drug entrapment and a prominent delay of drug release, 
satisfying the requirements of a chronotherapeutic approach for RA through 
the proper fine-tuning of prilling parameters.  
Results showed that prilling was a suitable microencapsulation technique to 
produce chronotherapeutic drug delivery systems (ChDDS) of NSAIDs with 
different solubility features (K and KL), using polysaccharide carriers, alginate 
and ALM-pectin properly crosslinked with Zn ions. 
In the second part of the project, our goal was  to  fully  realize  the   potential   
of  the prilling technology   by  creating appropriate carrier systems for SAIDs 
(Steroidal anti-inflammatory drugs) that would be specifically designed to 
improve the administration of prednisolone addressing the requirements of a 
chronotherapeutic treatment of RA.  
SAIDs are widely used in RA management for their anti-inflammatory and 
immunosuppressive properties offering rapid symptomatic effects as for 
NSAIDs and in addition acting as “disease-modifiers” (Smolen, Aletaha et al. 
2016). In fact, they have the ability to inhibit the transcription of different 
cytokines and chemokines responsible of RA physiopathology (IL-1, TNF-a, 
IL-3, IL-4, IL-5, IL-6, IL- 8, IL-11, IL-12, IL-13) and macro-phage inhibitory 
protein (MIP) (Van der Velden 1998). However, they long-term use may lead 
to severe side effects like gastro-intestinal troubles, osteoporosis, muscle 
atrophy/myopathy, glaucoma, diabetes, cardiovascular and immune system 
complications (Schäcke, Döcke et al. 2002). The development of modified-
release SAIDs formulations may be useful  in treating the early morning 
symptoms of RA, reducing the well-known side-effects and improving the 
therapeutic efficacy (Alten, Döring et al. 2010; Alten, Holt et al. 2015). 
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Among different SAIDs, prednisolone and prednisone are the most widely 
used steroids for the oral therapy of chronic inflammation diseases because of 
their short half-life and relatively low side effects, compared to other SAIDs. 
The drugs are metabolically interconvertible, prednisolone being the 
pharmacologically active species. Both drugs are rapidly absorbed after oral 
administration with plasma half-lives of about 3.5h for prednisone and 2.8h for 
prednisolone. However, prednisolone bioavailability after the administration 
of an oral prednisone dose is approximately 80% compared to similar 
prednisolone dosage form. (Davis, Williams et al. 1978; Pickup 1979). 
Moreover, prednisolone administration seems to be preferable also in case of 
liver disease, because of the poor conversion of prednisone to prednisolone 
(Madsbad, Bjerregaard et al. 1980).  
Despite the number of scientific papers on controlled-release formulation of 
prednisolone (Okimoto, Miyake et al. 1998; Di Colo, Baggiani et al. 2006; 
Lau, Johnson et al. 2012; Skowyra, Pietrzak et al. 2015), there are currently no 
products available on the market following a chronotherapeutic approach of 
the early morning pathologies.  
For these reasons, engineered microparticles loaded with prednisolone as 
model SAIDs were produced by prilling technique, studying extensively all 
the formulation variables (polysaccharide concentration, drug polymer ratio, 
presence of other excipient) and prilling process conditions with special 
emphasis to the gelling process (nature of the crosslinking agent, its 
concentration, pH and temperature). 
Results from the previous researches and the acquired know-how suggest that 
alginate may be the polymer of choice for prednisolone delivery acting as 
carrier and drug release modifier (Auriemma, Del Gaudio et al. 2011; Aquino, 
Auriemma et al. 2012; Auriemma, Mencherini et al. 2013; Del Gaudio, 
Auriemma et al. 2014; Cerciello, Auriemma et al. 2015). 
To achieve our goal, three different technological strategies were followed: 
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 Development of basic prednisolone-loaded alginate beads produced by 
prilling 
This part of the research comprises   
- Study of the effect of divalent cations and their combination on the gelation 
process of alginate beads loaded with prednisolone (Part 1)  
- Study of the effect of the polymer concentration and drug/polymer ratio on 
the performance of alginate beads (Part 2)  
- In vitro/in vivo characterization and selection of optimized prednisolone-
loaded beads (Part 2) 
 Development of a more complex drug delivery technology platform  
The design of a more “smart” and efficient oral platform for prednisolone 
delivery was based on drug-carrying beads showing the best in vitro 
performances and their charging  into specific DR® capsules, to obtain final 
dosage form able to further delaying the drug release (Part 2). 
 Design and formulation of floating alginate beads and their in vitro/in 





















SECTION B PART1: 
Study of  the effect of divalent cation and their combination on 











Based on the article: A. Cerciello, P. Del Gaudio, V. Granata, M. Sala, R. P. 
Aquino, P. Russo. “Synergistic effect of divalent cations in improving 




3-B 1.1 Specific aim 
Gelling solution parameters are critical variables in ionotropic gelation process 
and, consequently, their setting is one of the main purpose in prilling 
technique. The nature of the gelation bath/solvent, the selected crosslinking 
agent and its concentration as well as temperature and pH have functional 
relationship with gelling time, gel viscosity and beads strength. Moreover 
these key parameters may influence the technological characteristics of the 
final beads, such as drug entrapment, morphology and size, swelling and 
release behaviour as well as in vivo performance of the beads. 
In this part of my PhD project, special attention was focused on the study of 
the effect of cross-linker agents on microparticles formation and 
characteristics, examining the possibility to use a combination of two divalent 
cations and aiming to exploit the positive features of individual cations, 





While some papers reports on alginate beads produced with different cations 
(Das and Senapati 2008; Jay and Saltzman 2009), few researchers refers on the 
simultaneous use of two cationic crosslinkers (Chan, Jin et al. 2002). 
Literature survey shows that calcium is the most used divalent cation in 
alginate hydrogels formation able to realize a three dimensional lattice of 
ionically crosslinked polymer chains. Ca
2+
 ions preferentially interact with the 
polyguluronic acid units (GG) of alginate in a planar two-dimensional manner, 
while producing the so-called ‘‘egg-box’’ structure (Chan, Jin et al. 2002). In 
contrast to the efficiency of calcium-alginate interactions, matrix swelling and 
drug release from Ca
2+
-alginate beads seems to proceed rapidly in simulated 
biological fluids, both in gastric and in intestinal fluids, making Ca
2+
-alginate 
beads not applicable as oral controlled DDS (Østberg, Lund et al. 1994; Taha, 
Nasser et al. 2008). In fact as reported from El-Kamel et al., the release of 
diltiazem hydrochloride from Ca
2+
-alginate beads tested in simulated gastric or 
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intestinal fluid was very high (between 50-100% after 2h) (El-Kamel, Al-
Gohary et al. 2010). This effect is probably due to the high susceptibility of 
calcium beads to the ions present in the dissolution fluid (Østberg, Lund et al. 
1994), in fact only when pure water was used for dissolution tests Ca
2+
-
alginate beads result able to control the drug release (Aslani and Kennedy 
1996). 
On the contrary, as reported in the previous sections and confirmed in 
literature, the use of Zn
2+
 seems to be more suitable for the design of alginate 
hydrogels, prolonging drug release (Taha, Nasser et al. 2008; Cerciello, 
Auriemma et al. 2015).  




 alone or 
blended in different ratios into the gelling solution. Their effect on hydrogel 
formation and properties, including particle size, morphology, and ability to 
encapsulate the drug were evaluated, inner matrix distribution and factors 
affecting drug release were also studied.  
3-B 1.2 Gel-beads production and characterization 
Preliminary, based on the previous experience (Aquino, Auriemma et al. 2012; 
Auriemma, Mencherini et al. 2013), operative parameters of the prilling 
apparatus were set and alginate concentration into the feed solution at 2.00 %( 
w/v) and drug polymer ratio at 1:5 were used. 
A 600 µm nozzle was employed with a vibration frequency of 350 Hz,  (100% 
of amplitude) and  the flow rate was fixed at 6 ml/min. The droplets produced 
by the laminar jet break up, were collected into an aqueous solution (0.5M; pH 




ions or their mixtures (1:1, 4:1, 1:4), where they were 
gelled under gentle stirring. The beads were held into the gelling solution for 2 
min at room temperature, then recovered with a sieve and thoroughly rinsed 
with deionized water. Finally, the hydrated gel-beads were dried to increase 
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product handling and stability by air exposure at room temperature (22 
◦
C; 
67% RH) for several hours (12–18 h) until constant weight was reached.  
Blank (b) and P loaded alginate beads were produced (table IV), varying the 










Table IV. Alginate based beads loaded with P using different crosslinking agents. 
(alginate 2.00 w/v; drug polymer ratio  1:5).  Formulation code, gelling cation, actual drug 
content, encapsulation efficiency and micromeritics of dried beads obtained by 






















 / / 1.60 ± 0.06 0.93 ± 0.02 
F2 Zn
2+
 10.9 ± 0.3 65.6 ± 1.9 2.66 ± 0.13 0.90 ± 0.02 
F2_b Zn
2+






























(4:1) / / 1.72 ± 0.09 0.93 ± 0.02 
 
The beads were evaluated for particle size, entrapment efficiency, in vitro drug 
release examined in simulated gastric fluid (pH 1.2) and simulated intestinal 
fluid (pH 6.8), swelling ability, surface and inner characterization using a 
scanning electron microscopy (SEM). SEM images demonstrated the structure 
and surface of the beads; SEM-EDS highlighted the structure and the cations 
distribution in cryo-fractured particles. Differential scanning calorimetry 




All batches showed good results in terms of encapsulation efficiency (EE 
>60%, table IV). In particular, Ca
2+
-alginate beads (#F1) showed the higher 
EE value (77.4%), compared to Zn
2+
-alginate beads (#F2, 65.6%). This effect 
may be related to calcium hard electrophile nature, able to quickly establish 
electrostatic interactions with guluronic (G) groups of alginate; the softer ions 
like zinc, instead tend to slowly form covalent-like bonds with carboxylate 
groups of G and mannuronic (M) alginate moieties (Aiedeh, Taha et al. 2007; 
Taha, Nasser et al. 2008).  




into the gelling medium affected the drug 
encapsulation efficiency (#F3-F5 71.8-82.1%) due to a combination of the 
highest diffusivity of calcium ions and the highest ability of zinc ions to 









) (Hazel and Sidell 1987) induces the formation of a gel layer around the 
falling droplets of the feed solution, able to reduce drug leaking during the 
formation of the gelled beads. The slower co-gelling agent (Zn
2+
), acting into 
the medium, was able to produce a tougher polymer matrix by increasing the 
coordination with carboxylate groups (G and M residues). Therefore, the ratio 
between the two cations may play a very important role in drug encapsulation 
process and derived beads properties.  




 ratio the value of EE was around 






amount as in 4:1 ratio 
(#F5) the EE increased to 82% suggesting a synergistic effect of both cations. 
SEM analyses, combined to image J software elaboration, allowed identifying 
the main characteristics in terms of structure, surface as well as mean diameter 
and sphericity coefficient (SC). As reported in Table IV, all beads showed 
satisfying SC values ranging from 0.88 to 0.94. Independently from the cation 
used, blank formulations exhibited better SC values compared to P loaded 





Figure 26. Alginate based beads loaded with P using different crosslinking agents. SEM 
microphotographs of blank beads: F1_b (a), F2_b (d), F5_b (g) and corresponding P loaded 
formulations (surface and cryo-fractured): F1 (b-c), F2 (e-f), F5 (h-i). 
 
Results showed that particle size  appears a cation-dependent characteristic.  




- beads presented a mean 
diameter around 1.6 mm, whereas blank Zn
2+
-particles showed a mean 
diameter around 2.3 mm; the combination of the two cations, as gelling agent, 
produced beads with a mean diameter from 1.7 to 1.9 mm, related to the 
cations ratio, the higher the Zn
2+
 the larger the size.  
Generally, in addition to a higher roughness, prednisolone loaded formulations 
exhibited larger mean diameters compared to the corresponding blank beads, 
confirming the cation-dependent particle sizes behaviour. In fact, #F1 (Ca
2+
-










 in different ratios (#F3-F4-#F5), displayed a reduction in 
mean diameter (between 2.1 and 2.3 mm) compared to Zn
2+ 
alone based 
formulation F2 (2.7 mm), confirming that the high diffusivity of calcium ions 
was able to reduce droplets enlargement during gelling process. 
To better understand the structure of the inner matrix, dried particles were 
cryo-fractured and analysed by SEM. As reported in figure 26-c-f-i, P loaded 
formulations showed a compact and well-organized inner texture, thanks to the 
interaction between sodium alginate and the cross-linkers alone or in mixture, 
as well as to additional hydrophobic interactions that may occur between the 
drug and the polymer. 





(F3_b-F4_b-F5_b), showed texture and the real cation-distribution in 
the cross-linked matrix. 
As shown in figure 27, the cross-linkers ratio influences their distribution into 









4:1) formulations exhibited an internal structure enriched in Ca
2+
, due to the 
higher diffusivity of this cation, compared to Zn
2+
. Only when the Zn
2+
 




 1:4) it was possible to 
observe an equilibrium between the two cations into the polymeric matrix (# 




Figure 27. Alginate based beads loaded with P using different crosslinking agents. SEM 
and SEM-EDS microphotographs of cryo-fractured blank beads: F3_b (a), F4_b (b) and F5_b 
(c). 
 
To fully characterize the beads, DSC analyses were performed on 
prednisolone raw material, blank and P loaded formulations.  
 
Figure 28. Alginate based beads loaded with P using different crosslinking agents. DSC 
thermal profile of formulations: F1_b (a), F2_b (b), F3_b (c) compared to P raw material (d) 
and P loaded formulations  F1 (e), F2 (f), F3 (g). 
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As reported in figure 28-A, blank formulations showed a similar thermal 
behaviour: a first endothermic event between 80°C and 120°C related to the 
loss of water adsorbed by the hydrogel matrix, followed by a second 
endothermic event at 160°C for F1_b and F3_b and at 140°C for F2_b. 
Moreover, all formulations exhibited an exothermic event that was detected at 
higher temperatures in F1 and F3 (250°C - 260°C) attributable to the oxidative 
degradation of cross-linked matrix. Similarly, P loaded formulations (Fig. 28-
B) showed the same thermal events shifted at higher temperatures close to the 
melting point of the active compound.  
In addition, the thermal signal related to the melting point of P raw material 
was not detected in all P loaded formulations as effect of its effective inclusion 
into the alginate matrix after prilling process. Furthermore, it is interesting to 
point out that the encapsulation of the drug promotes an increase of the water 
absorbed from hydrogels, independently from the gelling agent.   
Swelling behaviour and drug release studies  
Swelling and dissolution experiments were conducted on P loaded 
formulations by means of an USP apparatus II  according to the change pH 
protocol described in the USP 36.  
 
Figure 29. Alginate based beads loaded with P using different crosslinking agents. 
Swelling profiles of #F1 (white bars), #F2 (black bars) and #F5 (black/white bars) in SGF (up 
to 120 min) and in SIF (from 120 to 150 min). 
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As reported in figure 29, swelling profiles of beads clearly reflected alginate 
properties: during the transit in the acid environment, a particle swelling is 
observed due to the penetration of H3O
+
 ions, even if the matrix preserved its 
integrity, as evidenced by the low drug release in this medium (Fig 30), 
occurring through a diffusional/erosive mechanism. This swelling is higher for 
Ca-alginate (#F1, SR= 0.64 after 120 min), where the calcium is entirely 
substituted by H3O
+
 ions, compared to Zn-alginate (#F2, SR=0.42 after 120 
min) and Ca/Zn-alginate (#F5, SR=57% after 120 min) beads. Changing the 




, a reduced swelling for F2 and F5 compared to 
F1 was observed, and it may be  responsible for a lower P release (Fig 30). 
 
Figure 30. Alginate based beads loaded with P using different crosslinking agents. Drug 
release profiles from formulations F1 and F2 (A); F3, F4 and F5 (B) compared to P raw 
material. 
 
These results supported some literature data, about the poor ability of calcium 
made systems in retaining drug release in simulated biological fluids, 
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compared to zinc based systems, able to create a tougher matrix thanks to a 
higher coordination with polymer moieties (Taha, Nasser et al. 2008; Al-
Otoum, Abulateefeh et al. 2014).  
However, after changing the pH, particle dimensions depend on both swelling 
and erosion 
processes, this latter occurring for the alginate chains rapid hydrolysis in 
simulated intestinal fluid (SIF). The erosion process was faster for F1 and F2 
microspheres, causing the complete disintegration of the beads in about 20 and 
25 minutes, respectively (Fig. 29). The phosphate ions in SIF determine, in 
fact, the capture of cations from the cross-linked polymeric systems, causing 
their dissolution with consequent prompt release of P encapsulated (Caballero, 
Foradada et al. 2014). Therefore, as pointed out in figure 30-A, alginate 
microspheres crosslinked with Zn
2+
 (F2) were better able to control P release 
in SGF but, as Ca
2+
-alginate particles, they failed in sustaining drug release in 
SIF.  





, showed in SGF a dissolution profile similar to F2, with a lower P release 
respect to #F1 (about 30% vs 40%), followed by a more sustained drug release 
profile in SIF. In fact, after 1 hour in this medium (t=180 min), only 59.5%, 
73.8 % and 86.3 % of P was released from formulations F5, F3 and F4 
respectively; while at this time point the complete release of the drug was 
achieved from F1and F2 microspheres. 
This trend highlighted the ability of zinc and calcium ions, when properly 
mixed, to assemble a more resistant polymeric matrix able to prolong drug 






Such effect could be related to the ability of zinc and calcium to bind alginate 
at different sites: while Ca
2+
 preferentially interact with guluronic (G) blocks, 
zinc cations are less selective, interacting with both G and mannuronic (M) 
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sites on the alginate molecules and resulting in a huger crosslinking of the 





 were in the ratio 4:1.  
The evaluation of release kinetics allowed to calculate P diffusion coefficient 
in the different formulations. In both SGF and SIF Higuchi’s model (see 
materials and methods section) showed the poorest performance whereas good 
fitting capacity was demonstrated by Peppas-Korsmeyer’s equation (as 
reported in materials and method section).  











, respectively. These results indicated that diffusion of P is influenced 




that producing a tougher matrix is 
able to strictly control drug diffusion. The diffusion process follows a complex 
non-Fickian release mechanism governed by matrix relaxation and erosion 
phenomena. 
3-B 1.3 Conclusions 









) in different ratios (1:1, 1:4 or 4:1) on technological 
properties of alginate beads loading SAID was investigated. Particularly, the 
crosslinkers’ influence on the efficiency of encapsulation, swelling and drug 
release properties was studied, using prednisolone as SAID.  




in opportune ratio evidenced a synergistic effect 
of the two cations, showing a series of significant improvements of the particle 
performance affecting positively both the encapsulation efficiency and the 
control of the swelling ability as well as drug release from the polymeric 




 ratio 4:1) resulted as an interesting formulation 
with high P entrapment (82%) and delay of its release up to 4h. 
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The best formulation exploited the Ca
2+
ability of establishing quicker 
electrostatic interactions with G groups of alginate and the Zn
2+
 ability to 
















SECTION B PART 2:  
Study of the effect of alginate concentration as well as 
drug/polymer ratio on alginate beads 
 
 In vitro/in vivo characterization of optimized microparticles and 
selection of prednisolone-carrying beads; 






Based on the article: A. Cerciello, G. Auriemma, S. Morello, R.P. Aquino, P. 
Del Gaudio, P. Russo. “Prednisolone delivery platforms: Capsules and Beads 





3-B 2.1 Specific aim 
The part 1 of this section pointed out that, the proper selection and 
combination of crosslinking agents are important parameters that profoundly 
characterize the technological properties of alginate carrying prednisolone 
microparticles (Alg.-P) produced by prilling technique. 
In fact, the drug entrapment (up to 82%) as well as the drug release (delayed 
up to 240 min) resulted strictly influenced by the two different cross-linkers 
selected. 
In this section, the effect of other formulation parameters as alginate 
concentration and P/alginate ratio, on Alg.-P technological properties and 
performances, was studied.  
Different alginate concentrations as well as P/alginate ratios were tested to 
produce gel-beads by prilling; the obtained microparticles were characterized 
in terms of morphology, solid state characteristics swelling properties and drug 
release profile using well established methods (UV, SEM, DSC, FT-IR, USP-
II dissolution). 
Moreover, to verify whether the delayed in vitro drug release as effect of the 
particle engineering process may induce in vivo a delayed/prolonged activity 
(Cerciello, Auriemma et al. 2015) the in vivo anti-inflammatory effect of the 
optimized SAID formulation, compared to prednisolone raw, was studied 
using the carrageenan-induced acute oedema in rat paw (male Wistar rats) 
model, with a modified induction-administration protocol. 
Moreover, the chance to combine the controlled release properties of SAID 
gel-beads with the peculiar features of DR® capsules was evaluated to obtain a 






3-B 2.2 Gel beads production and characterization 
Six loaded formulations, were produced by prilling using a 600 µm nozzle 
with a frequency of vibration of 350 Hz (amplitude 100%) with a feed solution 
flow rate fixed at 6.00 ml/min. 
Zn was used as crosslinking agent (10% w/v) in an aqueous solution at room 
temperature with pH= 1.5, and the gelling time was set at 2 min. 
Gel-bead formulations (#F1 – #F6) were obtained varying:  
- Alginate (alg) amounts (from 2.0 % to 2.5 % w/v)  
- and drug/polymer mass ratios (1:10 and 1:5 w/w),  
- using a very short processing time in the selected operative conditions.  
As control, blank Zn-alginate beads were also produced (F). Drying process 
was conducted by exposing hydrated beads to standard room conditions (22 
°C; 67% RH) for 12–18 h until constant weight was reached. 
 
Table V. Zn-alginate based beads loaded with P. Composition, actual drug content, 
encapsulation efficiency, mean diameter and sphericity coefficient of formulations F-F6 










(% ± SD) 
EE
 
(% ± SD) 
Dried beads 
diameter  
(mm ± SD) 
SC 
F 2.50 - - - 2.4 ± 0.15 0.93 ± 0.01 
F1 2.00 1:10 6.2 ± 0.2 67.9 ± 2.0 2.4 ± 0.12 0.91 ± 0.02 
F2
 2.00 1:5 11.7 ± 0.6 69.9 ± 3.8 2.7 ± 0.13 0.90 ± 0.02 
F3 2.25 1:10 6.6 ± 0.3 72.8 ± 3.4 2.4 ± 0.12 0.90 ± 0.01 
F4 2.25 1:5 12.3 ± 0.4 73.6 ± 2.3 2.5 ± 0.12 0.91 ± 0.02 
F5 2.50 1:10 6.8 ± 0.2 74.3 ± 2.0 2.4 ± 0.12 0.92 ± 0.02 




Actual drug content (ADC) and encapsulation efficiency (EE) values of all 
dried formulations ranged from 67.9 to 78.6 % (Table V) in relation to the 
amount (from 2 to 2.5%) of alginate used as well as to the drug/polymer ratio 
(from 1:10 to 1:5) selected. 
In fact, the highest ADC and EE values were obtained raising drug/polymer 
ratio and alginate amount into the feed solutions. These data were consistent 
with previous observations on polysaccharides based hydrogels loaded with 
NSAIDs, suggesting that the loading of higher amount of drug and an 
increased polymer concentration may promote, during the gelation phase, 
intermolecular interactions able to stabilize the “egg-box” structure (Cerciello, 
Auriemma et al. 2015; Cerciello, Auriemma et al. 2016), reducing the leaching 
of the drug from the droplets into the gelling medium. Accordingly, #F6 (alg. 
2.5%, drug/polymer ratio 1:5) showed the best P entrapment within the matrix 
(EE = 78.6 %).  
 
Figure 31. Zn-alginate based beads loaded with P. SEM microphotographs at different 




Polymer and drug concentration in the processed feeds influenced the surface 
properties of the particles: drug-free beads (#F, figure 31, a) were smoother 
without wrinkles, whereas P loaded beads had all an irregular surface and 
roughness directly related to P and polymer content. In particular, the higher 
the content of drug and the polymer concentration, the greater the surface 
roughness. Moreover, no drug crystals were observed on the particle surface 
(#F1-F6, figure 31 b-g) and all particles showed similar morphological 
characteristics in terms of sphericity coefficient (SC 0.90 - 0.92) and mean 
diameter values (2.4 – 2.7 mm) (Table V).  
These data suggested that the optimization of operative and process variables 
during prilling/ionotropic gelation process (Zn
2+
concentration, pH, 
temperature and curing time) was able to produce beads with almost spherical 
shape in a narrow dimensional range, independently from the amount of 
alginate or to the drug/polymer ratio selected.  
 
Figure 32. Zn-alginate based beads loaded with P. SEM microphotographs of cryofractured 




To better understand the influence of drug content and alginate amount on the 
inner structure, beads were cryo-fractured prior to SEM observation.  
The blank Zn-alginate beads revealed a compact inner matrix (#F Figure 32 d). 
On the contrary, the internal structure of all engineered particles was less 
continuous and interrupted by several empty folders (Figure 32 a-b, red 
circles), depending on the polymer and drug concentration into the liquid feed 
processed.  
Moreover, the images suggested that the increase of alginate (from 2.25% to 
2.50%, Figure 32 a-c) and drug concentrations (from 1:10 w/w to 1:5 w/w, 
Figure 32 b-c) induces a higher organization of the matrix, desirable for the 
development of oral controlled drug delivery systems.  
In order to assess the matrix resistance in biological fluids, swelling 
experiments were conducted in SGF and SIF, following pH change methods 
steps. Formulation F6 exhibited in SGF a swelling degree of about 13% after 
60 min and 58% after 120 min. Beads presented at both time points smoother 
surface and higher particle sphericity compared to dried particles. 
Interestingly, drug loaded beads exhibited the maximum swelling degree 
(76%) at 135 min, as a result of enhanced water penetration and slow 
beginning of the erosion process in SIF. After this time point, the erosion 
overtakes the swelling, leading to a complete particle disintegration at 190 
min.  
In order to highlight feasible drug-polymer interaction after prilling process, 
thermal profiles of P raw material, blank Zn-alginate beads and drug loaded 






Figure 33. Zn-alginate based beads loaded with P. DSC thermograms of P raw material (a), 
alginate blank beads F (b) and drug loaded formulations F5 (c) and F6 (d). 
 
P raw material exhibited a clear endothermic peak at 252˚C followed by an 
exothermic event between 280 and 350 ˚C corresponding to its oxidative 
degradation. Both empty and P loaded formulations exhibited an opening 
endothermic event between 90 and 130 ˚C related to the loss of water adsorbed 
on the particle surface and entrapped into the matrix. Blank Zn-alginate beads, 
showed a broad endothermic signal between 150 and 182˚C followed by a 
ramp like event up to 260 ˚C. The endothermic peak due to the fusion of 
crystalline P (252 ˚C) disappeared in  drug loaded beads thermograms (fig. 33, 
c-d) suggesting a complete drug entrapment; moreover, melting as well as 
degradation peaks were shifted to higher temperatures in F5 and F6 thermal 
profiles with respect to blank Zn-alginate beads. These effects, more 
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pronounced in F6, suggested a physical alginate/P interaction as effect of drug 
loading in the polymeric matrix (Cerciello, Auriemma et al. 2016). 
In order to verify the presence of such interaction suggested by DSC analysis, 
FT-IR studies were performed and results reported in Figure 34.  
 
 
Figure 34. Zn-alginate based beads loaded with P. FTIR spectra of P raw material, 
formulations F5-F6 and Zn-alginate blank beads F. 
 
P raw material exhibited two characteristic bands in the range 1590-1710 cm
−1 
corresponding to symmetric and antisymmetric stretching of C=O aliphatic 
group (Palanisamy and Khanam 2011; Mazurek and Szostak 2012). The FT-IR 
spectrum of Zn
2+
 crosslinked alginate blank beads presented bands at 1650 and 
1425 cm
−1
 corresponding to the stretching of symmetric and antisymmetric 
carboxylic groups of the Zn-alginate complex and due to the coordination 
between the metal ion and the functional groups of the polymer 
(Papageorgiou, Kouvelos et al. 2010). #F5 and #F6 showed the majority of the 
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characteristic peaks of both Zn-alginate and prednisolone, however at 1703 
cm
-1
 a new band was recognized, which could be associated to the interaction 
between P and alginate chains via Zn
2+
 coordination.  
Drug release studies 
Dissolution studies of prednisolone raw material and produced beads were 
performed using USP Apparatus 2 and a classic pH-change assay. The 
dissolution profiles of F2, F4 and F6 characterized by the highest 
drug/polymer ratio (1:5) are shown in figure 35. 
 
 
Figure 35. Zn-alginate based beads loaded with P. Release profiles of P from: raw material, 
square; # F2, diamond; # F4, circle and #F6, triangle. Mean ± SD; (n=6). 
 
As expected, the dissolution profile of P raw material was typical of 
compound belonging to the class I of the Biopharmaceutical Classification 
System (high solubility and permeability trough biological membranes), the 
complete solubilisation was achieved in simulated gastric environment after 
about 90 minutes (Sugawara, Imai et al. 1994). Differently, F2, F4 and F6 
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showed a partial gastro-resistance. In particular, as shown in figure 35, #F6 
obtained with the highest alginate amount exhibited the more interesting 
dissolution profile, releasing only 24.1% of the drug in simulated gastric fluid 
(SGF) followed after the pH change by a more sustained release in simulated 
intestinal fluid (SIF) with respect to #F4 and #F2 (100% of P release after 
about 3.5h). All formulations seem to release the drug through a 
diffusional/erosional mechanism. However, the greatest alginate amount as in 
#F6 seems to be able to better retain the drug during its exposition to 
simulated biological fluids. Conversely in SIF (at pH 6.8) beads started to 
swell and further erode due to the ion-exchange process.  
Therefore, formulation F6 showing the best performances in vitro (drug 
content, inner matrix texture, drug release) was selected for the in vivo 
experiments in order to evaluate a potential delay of anti-inflammatory effect 
compared to reference prednisolone. 
In vivo experiments 
As previously reported for NSAIDs, the possibility to study in vivo the anti-
inflammatory effect of formulations showing good in vitro features, may be an 
important tool for the development of a ChDDS. 
For this reason, also the more interesting SAID formulation, F6, was 
administered to rats by oral gavage using a modified protocol of carrageenan-
induced oedema model and the anti-inflammatory activity of F6 beads was 




Figure 36. Zn-alginate based beads loaded with P. Oedema volume reduction obtained by 
administering per os pure prednisolone (A) and #F6 (B) at different  time points (15, 5, 0.5h) 
to rats before carrageenan injection, compared to control; mean ± SEM (n = 8). *p < 0.05, **p 
< 0.01 compared to control. 
 
Preliminary experiments were performed by using three different doses of 
prednisolone (1-3-10 mg kg
-1
) administered by gavage to rats 0.5h before 
carrageenan injection (data not shown). The dose of 3 mg kg
-1
 of prednisolone 
was selected as it achieved the optimal anti-inflammatory effect. The pure 
drug (3 mg kg
-1
, prednisolone) was significantly efficacious in reducing rat 
paw oedema when administered at t=0.5h before carrageenan injection (figure 
36-A). The anti-inflammatory activity of prednisolone was lost when 
administered to rats 5h or 15 h before the phlogistic agent injection (figure 36–
B).  
To verify a potential delayed/prolonged in vivo anti-inflammatory activity, as 
effect of an accurate particle engineering process, F6 in dose equivalent to 3 
mg kg
-1
 of prednisolone was orally administered to rats 5h and 15h before 
carrageenan injection. The administration time points were extended (5h and 
15h) compared to those for NSAIDs (Zn-alginate beads Section A part 1) 
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according to the different mechanism of action and pharmacological properties 
of prednisolone.  
Results showed that F6, significantly reduced carrageenan-induced paw 
oedema in rats when administered 5h before the injection of the phlogistic 
agent (Figure 36-B).  
The anti-inflammatory activity of F6 still persisted  when administered to rats 
15h before carrageenan injection (Figure 36-B), in contrast to reference 
prednisolone (3 mg kg
-1
) that was efficacious in reducing rat paw oedema only 
at t=0.5h (figure 36-A). As previously reported (Cerciello, Auriemma et al. 
2015), blank Zn-alginate beads (F) did not significantly affect the paw oedema 
when administered to rats at the same time points before oedema induction 
(data not shown), thus, indicating that alginate and zinc do not interfere with 
the inflammatory process.  
In vitro drug release from the final dosage form 
Formulation #F6, acting as a partially gastro-resistant and sustained release 
formulation and able to exert the anti-inflammatory activity even if 
administered 15h before the phlogistic injury, was selected as core material for 
the development of a final dosage form suitable for a chronotherapy. 
Therefore, #F6 was hosted into DR
®





 capsules were previously used to control/delay the release of KL from 
ALM-pectin beads (Section A part 2), since among different capsules models, 
they exhibit specific feature in protecting API from acidic environment thanks 
to the properties of a mixture of hydroxypropyl methylcellulose (HPMC) and 




Figure 37. Zn-alginate based beads loaded with P. Release profiles of : P raw material 
hosted into DR
®
 capsules (square) compared with optimized F6/DR
®
 final dosage form 
(triangle). Mean ± SD; (n=3). 
 
The resulting dissolution profile of P from F6/DR
®
 cps versus more 
conventional P/DR
®
 cps profile showed that DR
®
 caps were able per se to 
delay the dissolution profile of prednisolone (figure 37), extending its release 
from 90 to 180 minutes with a significant reduction in SGF (34.2%). 
Interestingly, the final dosage form F6/DR
®
 cps reduced significantly P release 
in SGF from 24.1% to 12.6%; at the same time, after pH change, P dissolution 
was significantly delayed up to about 390 minutes (6.5 hours).  
This very interesting drug release profile was due to combination of intrinsic 
properties of capsules and hosted beads; only after the dissolution of the 
capsule body, beads are exposed to the dissolution medium, beginning later 
the dissolution process. Differently from gelatin capsules that normally 
disaggregate in simulated gastric fluid in about 5 minutes, the DR
®
 capsules 
begin to disaggregate after 75-90 minutes protecting the formulation from the 
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acid environment. After this lag time, beads start to hydrate and swell, 
allowing a slight drug diffusion in acidic medium followed by a complete but 
delayed swelling and erosion processes in SIF. 
3-B 2.3 Conclusions 
This part of the PhD project, was aimed to study the effect of process and feed 
solution variables (alginate concentration and drug/polymer ratio) on particles 
size, morphology, solid state properties and drug release profile of 
prednisolone microparticles produced by prilling Particles prepared from 
solution containing the highest amount of polymer and drug showed good 
production parameters such as high encapsulation efficiency (around 80%) and 
strongly crosslinked inner matrix as evidenced by SEM pictures of cryo-
fractured beads. Moreover, engineered particles showed a reduced P release in 
gastric simulated environment and a slow release in simulated intestinal fluid, 
compared to conventional P.  
The prolonged in vivo anti-inflammatory effectiveness of formulation #F6 
tested by a carrageenan-induced oedema model clearly reflects its ability to 
release the drug in a delayed and sustained way, highlighting its potential 
benefits for a right chronotherapy. 
Finally, the optimized formulation F6 was selected for the manufacturing of a 
final dosage form, using DR
®
 capsules chosen for their peculiar dissolution 
properties. By designing a more complex platform, hosting F6 beads in DR
®
 
capsules, it was possible to further delay and prolong P release, up to 6.5 
hours. The platform (#F6/ DR
®
) used in the present study, therefore, 
represents a suitable dosage form able to delay and extend SAID release in a 














SECTION B PART 3: 
 Design and formulation of floating alginate beads and their in 















3-B 3.1 Scientific background and specific aim 
Results of the previous research (Section B part 1-2) have shown how the 
control/delay of prednisolone  release may be obtained through engineered 
particles based on Zn-alginate matrix and proper selection of the polymer 
concentration, drug/polymer ratio above crosslinking agent. The selected 
variables may led  to the formation of a compact alginate matrix able to delay 
P release for several hours in intestinal environment (Cerciello, Auriemma et 
al. 2016). 
Another approach to ensure drug delayed release may be the development of 
floating alginate beads able to act via an extension of the drug gastric 
residence time (GRT). 
Generally, floating formulations are one of the most employed technological 
approaches to produce gastro-retentive (GR) drug delivery systems with 
prolonged GRT (Chaturvedi, Prabha et al. 2013; Nayak, Upadhyay et al. 
2014). GR-floating formulations are low-density systems that have sufficient 
buoyancy to float over gastric contents and remain in the stomach for 
prolonged period without affecting gastric emptying rate and, at the same time, 
release the drug slowly (Ramteke, Jadhav et al. 2012). 
In the last few years, NSAIDs or SAIDs floating formulations (i.e. diclofenac 
sodium, indomethacin, acetylsalicylic acid, ibuprofen, naproxen, ketorolac, 
prednisolone) have been successfully developed in form of single-unit dosage 
forms (powders, granules, capsules, tablets, laminated films) or multiple-unit 
formulations (Singh and Kim 2000; Badve, Sher et al. 2007; Ramteke, Jadhav 
et al. 2012; Ware, Tiwari et al. 2013; Gifty, Behin et al. 2015; Radwan, Abou 
el Ela et al. 2015).  
In particular, microparticles able to float appear particularly interesting; in 
fact, the distribution of the multiple-unit dosage forms in the stomach is more 
uniform than that of single-unit dosage forms. As a result, floating 
microparticles may induce a more reproducible drug absorption as well as 
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reduce risks of local irritation (Sharma, Sharma et al.) and result potentially 
useful for the development of ChDDs. 
To achieve this goal, floating beads were prepared adding calcium carbonate, a 
gas-generating agent producing CO2 in acid conditions, to the base-formula 
(Zn-alginate 2.5% w/v, prednisolone/alginate 1:5_ see beads in section B part 
2), which entrapment in the gel matrix may confer an increased porosity and 
buoyancy ability (Verma, Sharma et al. 2013). 
Among different agents, producing CO2 in acidic conditions, (sodium 
carbonate, potassium carbonate, sodium bicarbonate, citric acid) (Choi, Park et 
al. 2002; Krishnan, Sasikumar et al. 2010), calcium carbonate was selected in 
order to assess the potential effect of calcium interactions with G groups of 
alginate, combined to the presence in the gelling medium of Zn ions on the 
produced microparticles.  
The effect of the addition of different amounts of calcium carbonate in to the 
feed solution on particle encapsulation efficiency, morphology as well as in 
vitro drug release profile was studied. 
Moreover, the ability of the floating beads to modulate in vivo the anti-
inflammatory response was studied using the carrageenan-induced acute 
oedema in rat paw (male Wistar rats) (Section B, part 2). 
3-B 3.2 Floating beads production and characterization 
A series of Zn-alginate formulations loaded with prednisolone was produced 
adding CaCO3 in the feed solution, as gas-generating agent, in order to obtain 
floating-gastroretentive systems. Carbonate salts when in contact with an acid 
medium  produced CO2 that entrapped in a hydrogel matrix reduced the system 
density conferring buoyancy ability (Choi, Park et al. 2002; Verma, Sharma et 
al. 2013). 
Alginate concentration (2.5% w/v) and drug/polymer ratio 
(prednisolone/alginate ratio 1:5) were fixed on the basis of previous research 
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(Cerciello, Auriemma et al. 2016), while different Alg/CaCO3 ratio were 
studied.  
 
Table VI. Zn-alginate/calcium carbonate based beads loaded with P. Formulation code, 













(% ± SD) 
F1 
2.50% 
/ 78.6 ± 2.1 
F2 1 : 0.10 88.4 ± 2.9 
F3
 1 : 0.25 94.5 ± 1.7 
F4 1 : 0.50 87.8 ± 3.5 
F5 1 : 0.75 91.1 ± 2.1 
F6 1 : 1.00 91.1 ± 2.0 
 
As reported in table VI, all formulations produced showed EE values higher 
than F1, obtained without calcium carbonate, in the range of 87.8 – 94.5%. 
This effect could be explained by the presence of calcium carbonate into the 
feed solutions as an insoluble dispersion in neutral pH; during the ionotropic 
gelation process the polymer-CaCO3/drug droplets produced by prilling fall 
down into zinc acetate solution with an acidic pH (1.5) and CaCO3 became 
water-soluble. The Ca
2+  
ions promoted an internal gelation, by cross-linking 
the alginate carboxyl group (Choi, Park et al. 2002; Verma, Sharma et al. 
2013), which, in addition to the external gelation obtained by Zn
2+ 
ions present 
in gelation medium, allowed to incorporate an higher amount of drug.  
Moreover, in order to evaluate the effect of calcium carbonate on the inner 






Figure 38. Zn-alginate/calcium carbonate based beads loaded with P. SEM 
microphotographs of cryo-fractured zinc-Alginate beads: F6 (a) and F4 (b) at different 
magnifications. 
 
Particularly, in figure 38 the inner matrix of F6 and F4, obtained with a 1:1 
and 1:0.5 alginate/calcium carbonate ratio, were reported. The loading of a 
greater amount of CaCO3 caused the formation of a macro-porous structure 
(#F6, fig. 38-a-a1) due to a higher quantity of CO2 produced during the gelling 
phase. At the same time together with big pores, the presence of a micro-
porous structure, was detected for both formulations. In particular, porous 
diameter decreased significantly from F6 to F4 (84.94 µm - 21.76 µm, 
respectively, fig. 38 -a2 -b1) which resulted in a more compact inner structure 
without empty macro-porous (fig. 38 -b).  
The high porous nature of the produced microparticles suggested their 
potential suitability to float over the gastric fluids; so, for this reason, a 
buoyancy test in SGF was performed.  
The buoyancy ability of each formulation was evaluated by visual observation 
(number of floating beads/total number of beads used for the experiment*100) 
and expressed as floating percentage (FP). The time lag for the evaluation of 













F2 and F3 (alginate/calcium carbonate ratio 1:0.1 and 1:0.25 respectively), 
resulted unable to float in SGF; this result, was probably related to a calcium 
carbonate loading too low to produce pores in the matrix. 
Interestingly, F4-F5-F6 formulations resulted able to float in SGF up to 5h 
without any particles disintegration or erosion.  
Results showed as the buoyancy ability was directly related to the 
concentration into the feeds of the gas generating agent, with FP of 98.3%, 
84.0 and 77.3 for formulation F6-F5-F4 respectively.  
Hence, as pointed out from these results, an alginate/calcium carbonate ratio ≥ 
1:0.5 was able to produce buoyant beads with a total floating time of 5h. This 
prolonged FT may be due to low apparent density provided by the porous 
nature of the beads (Fig. 38); after this time point all the microparticles tend to 
sink. 
Dissolution experiments were, therefore, performed in SGF for 5h 
(corresponding to the detected floating time). 
 
 
Figure 39. Zn-alginate/calcium carbonate based beads loaded with P. Release profiles of  



























These three formulations showed a controlled P release in SGF and 
particularly formulation F4 exhibited the slowest P dissolution compared to F5 
and F6 (cumulative release of only 43 % t= 300 min). The porous alginate 
matrix (particularly in F4) resulted able to retain the drug during its buoyancy 
in SGF; this effect may be due to the high alginate crosslinking obtained with 
an internal gelation (Ca ions) added to an external gelation provided by Zn 
ions. 
The produced floating microparticles showed an interesting buoyancy ability 
in vitro and resulted able to control P release in SGF for a prolonged time (5h).  
F4, showing an interesting floating ability and the slowest in vitro drug 
release, was selected for the in vivo experiments in order to evaluate the 
potential ability of a porous formulation to modulate the anti-inflammatory 
effect in rats. 
In vivo experiments 
The potential efficacy in modulating the anti-inflammatory effect in vivo, of 
the porous formulation F4, was evaluated using the modified protocol of 
carrageenan-induced oedema in rat paw (male Wistar rats) used for 
prednisolone non-floating formulation (Section B, part 2) with administration 






Figure 40. Zn-alginate/calcium carbonate based beads loaded with P. Oedema volume 
reduction obtained by administering per os pure prednisolone, P (A) and #F4 (B) at different 
time points (15, 5, 0.5h) to rats before carrageenan injection, compared to control; mean ± 
SEM (n = 8). *p < 0.05, **p < 0.01, ***p ≤ 0.001 compared to control. 
 
As previously discussed, P raw failed to control the oedema volume when 
administered orally to rats 5h or 15h before carrageenan injection; on the 
contrary, as for non-floating formulation, F4 revealed still able to exert the 
anti-inflammatory effect in vivo when administered orally to rats up to 15h 
before oedema induction. 
This result was very interesting because for an hollow matrix as F4,  a fast 
drug release due to the high solvent penetration was expected leading to a 
reduced anti-inflammatory effect in vivo. Hence, we supposed that this 
delayed/prolonged in vivo anti-inflammatory effect of F4 was probably due to 
its ability to float in SGF that may reflect in vivo in a gastric residence time 
increase with a more controlled and sustained P release.  
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3-B 3.3 Conclusions 
Hollow gel microparticles able to sustain prednisolone delivery were produced 
starting from an optimized Zn-alginate matrix (alginate 2.5% w/v, drug/P ratio 
1:5) with the addition of calcium carbonate in the polymer/drug solution. The 
opportune selection of the gas generating agent, produced beads with high EE 
values (up to 94.0%), a porous inner matrix when alginate/calcium carbonate 
ratio was ≥ 1:0.5. The hollow beads resulted able to float in SGF for 5h 
controlling at the same time P release. Interestingly, the best formulation F4, 
despite its hollow inner structure, resulted able to prolong the anti-
inflammatory effect in vivo up to 15h compared to reference prednisolone. 
Thanks to its potential ability to increase the GRT in vivo, as well as its 
intrinsic controlled/delayed release properties, F4 could be proposed as an 
interesting formulation to be further optimized. Other studied are necessary to 
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Gastroretentive systems to sustain piroxicam release: in vitro 











Based on the article: G. Auriemma, A. Cerciello, A. Pinto, S. Morello, R. P. 
Aquino. “Floating gastrorententive system for piroxicam sustained release: 




3-C 1.1 Scientific background and specific aims 
The previous sections of my PhD thesis, focused on the design and 
development by prilling/ionotropic gelation technique of ChDDS loaded with 
anti-inflammatory drugs with different chemical and pharmacological features 
(NSAIDs or SAIDs) all characterized by a short half-life. 
Based on the acquired know how with the formulation and process variables 
of the prilling technique, starting from Zn-alginate and Zn-ALM-pectin as 
polymeric carriers, a further challenge of my PhD project, was to design a 
ChDDS loaded with piroxicam (PRX) as model of  long half-life NSAIDs. 
PRX is commonly used in chronic inflammatory-based diseases such as 
rheumatoid arthritis and osteoarthritis, in controlling postoperative pain and 
acting as an analgesic drug. According to the biopharmaceutics classification 
system (BCS) and all current guidances (U.S. Department of Health and 
Human Services 2000; WHO 2006; European Medicines Agency EMA 2010), 
PRX is a BCS Class II drug with “low solubility” and “high permeability”. 
Being an amphoteric molecule, it is ionized under gastro-intestinal conditions, 
therefore its pH dependent solubility increases at low (1.2) and high (6.8) pH 
values and decreases in the middle pH range when the drug is in the not 
ionized form (Shohin, Kulinich et al. 2014). PRX is rapidly and completely 
absorbed after oral administration (recommended dose in adults is 20 mg 
daily) and exhibits a long half-life (24-48h). However, PRX elimination is 
impaired in some elderly people (Verbeeck, Richardson et al. 1986), who 
represent the majority of patients affected by rheumatic diseases, resulting in a 
high inter-individual variability in the steady state plasma levels. Sustained 
release dosage forms capable of steady release of the drug over prolonged 
periods may, therefore, overcome such variability due to erratic drug 
elimination (Joseph, Lakshmi et al. 2002). 
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The solution was sought in the development of a new floating/gastroretentive 
system able to increase the gastric residence time, thus controlling and 
sustaining PRX release.  
Therefore, a floating gastroretentive system carrying piroxicam was designed 
in form of hollow microspheres, using an opportune ternary matrix made up of 
hydrophilic swellable polymers (alginate and ALM-pectin) opportunely mixed 
with Hydroxypropyl methylcellulose (HPMC). HPMC has been selected as 
hydrocolloid with cellulose backbone having a bulk density less than 1 
(Hoffman 2002) which may act as an adjuvant in pore forming (Mukund, 
Kantilal et al. 2012). Interestingly, in this case the floating system was 
designed, without using any gas generating agent. As previously reported for 
alginate-calcium carbonate beads loading prednisolone (Section B part 3), it is 
not easy to predict and stabilize the opportune gas-generating agents amount 
that profoundly influences particles micromeritics, inner matrix, floating 
ability and dissolution rate.  
Different formulation parameters of prilling technique were studied, and 
mainly polymers mass ratio and viscosity of the feed solutions were 
investigated to establish the effect of these critical process parameters on 
hollow particles production, micromeritics, inner structure as well as on drug 
loading and in vitro drug release.  
Their potential ability to prolong the anti-inflammatory effectiveness in vivo, 
was evaluated using the consolidated model of carrageenan-induced oedema in 
rat paw using different induction/administration time points (0.5, 3, 5, 24 and 
48h before carrageenan injection) accordingly to PRX half-life.  
3-C 2.1 Gel-beads production and characterization 
The floating dosage form of piroxicam was designed as hollow gel-beads 
based on a ternary Alginate (ALG, Pol1), ALM-Pectin (PCT, Pol2) and 
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Hydroxypropyl methylcellulose (HPMC, Pol3) matrix using Zn as opportune 
cross-linker. 
Several PRX hollow beads were produced by prilling and the hydrated beads 
were dried to the final handling and stable form. The systems were 
characterized to evaluate the influence of each polymer, its concentration as 
well as gelling conditions on hollow beads formation, their inner structure and 
in vitro/in vivo release performances.  
As reported in Table VII, formulations F1-F4 were produced varying 
Pol1/Pol2/Pol3 mass ratio and reducing progressively final polymeric 
concentration whereas drug-polymer ratio was fixed at 1:15 on the basis of 
results from preliminary experiments. As control, blank beads were also 
produced. Drying process of the hydrated beads was conducted by exposing 
them to standard room conditions (22 °C; 67% RH) for 18–24 h until constant 
weight was reached. 
Table VII. Zn-ALG-ALM-Pct-HPMC beads loaded with PRX. Formulation code, 
polymeric carrier, drug content (ADC), viscosity, encapsulation efficiency (EE), mean 




















F1 1.75 : 4: 1.0 6.75 114.6 5.3 ± 0.1 85.2 ± 1.8 4076 ± 85 0.53 ± 0.01 
F2 1.75 : 3 : 1.0 5.75 75.8 5.0 ± 0.2 78.7 ± 2.1 3617 ± 186 0.66 ± 0.04 
F3
 1.75 : 3 : 0.5 5.25 74.5 5.4 ± 0.1 87.0 ± 1.3 2396 ± 129 0.86 ± 0.03 
F4 1.25 : 3 : 0.5 4.75 29.4 4.7 ± 0.1 74.0 ± 2.3 2209 ± 99 0.94 ± 0.01 
 
* Pol1: ALG; Pol2: ALM-Pct; Pol3: HPMC 
** spindle: R2; rotor velocity, ω: 20 rpm 
 
Results showed good ADC and EE values; as reported in Table VII, EE was in 
the range between 74% (F4) and 87% (F3). The slight reduction in EE value 
observed for F4 may be due to the decrease in viscosity of the polymeric 
solution that may allow a greater drug leaking to the cross-linking solution.  
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Interestingly, SEM analysis of the beads highlighted significant differences in 
terms of shape and sphericity. Surface analysis showed that F1, F2 and F3 
(6.75-5.25% w/w feed concentrations) particles have a very irregular and 
oblong shape correlated to the high viscosity of the feed solutions (Table VII) 
that may delay the break-up of the polymeric laminar-jet and, thus, droplet 
formation. The high entanglement existing between the chains of three 
different polymers makes the polymeric jet highly cohesive (viscoelastic 
stresses dominate) delaying drops detachment from the nozzle. At the lowest 
feed concentration (4.75 w/w) and viscosity (F4, 29.4 Pa*s), polymer chains 
are relaxed and surface tension dominates, allowing the formation of droplets 
that, falling in the gelation bath, give rise to spherical particles. In fact, SEM 
analysis of F4 showed beads spherical in shape with a SC mean value of 0.94 
and a mean diameter around 2200 µm (Fig.41-d).  
 
 
Figure 41. Zn-ALG-ALM-Pct-HPMC beads loaded with PRX. SEM microphotographs of 




For more information about inner polymeric texture, beads were cryo-
fractured and successively analysed by SEM (Fig. 42). The cross-section of 
beads showed either a hollow core (F1) or multiple small hollow pockets (F3-
F4) of the ternary matrix. The presence of air-filled hollow spaces inside the 
beads may be due probably to the pore forming ability of HPMC (Mukund, 
Kantilal et al. 2012).  
 
 
Figure 42. Zn-ALG-ALM-Pct-HPMC beads loaded with PRX. SEM microphotographs of 
cryo-fractured beads: F1 (a-b), F3 (b-c) and F4 (e-f). 
 
To study piroxicam solid state after prilling process, Fluorescent Microscopy 






Figure 43. Zn-ALG-ALM-Pct-HPMC beads loaded with PRX. FM microphotographs of 
PRX raw material (a), cryo-fractured F4 blank (b) and F4 PRX loaded beads (c). 
 
The FM images of pure PRX displayed crystalline material with blue 
fluorescence consisting of small crystals forming aggregates with a larger size, 
while images of blank particles (F4_blank) showed a reddish and off-white 
fluorescence in the inner and the outer, respectively. After the encapsulation 
process, PRX seems to keep its crystallinity and to be uniformly distributed 
within the hollow matrix. In fact, FM images of F4 (PRX loaded beads) 
displayed fluorescent spots due to PRX crystals homogeneously embedded 
within the hollow core. 
In order to have a full technological characterization, DSC experiments were 
performed. The DSC thermal profiles of PRX raw material, blank (F1_b) and 
PRX-loaded beads (F1-F4) are shown in figure 44. According to previous 
observations (Vrecer, Vrbinc et al. 2003), thermal profile of pure crystalline 
PRX (Fig. 44-a) exhibited a very narrow melting peak at 201 °C and a broad 
exothermic peak at 225 °C due to the oxidative degradation. The thermogram 
of blank beads F1_b (Fig. 44-b) showed two endothermic events, well 
separated in temperature values, at 110°C corresponding to the loss of 
hydration water (Pillay and Fassihi 1999; Cerciello, Auriemma et al. 2015) 
and 160°C due to the melting of the ternary polymeric matrix, followed by an 
exothermic signal (ramp-like event) ranging from 227°C to 265°C and due to 
matrix degradation. All PRX- loaded beads (Fig.44-c-d-e-f) showed a thermal 







peak of crystalline PRX is no longer detectable by DSC technique because, as 
previously reported, low-melting point polymers act as solvent for a crystalline 
drug embedded in a matrix (Del Gaudio, Auriemma et al. 2014). In this case, 
the ternary polymeric matrix begins to melt at lower temperature (160°C) than 
PRX (melting point 201°C), dissolving drug crystals in the melted polymers. 
PRX crystalline form is responsible of the exothermic signal at 312-322°C 
attributable to its oxidative degradation.  
 
Figure 44. Zn-ALG-ALM-Pct-HPMC beads loaded with PRX. Differential scanning 
calorimetry thermograms: PRX raw material (a), blank beads F1_b (b) and PRX loaded beads 
F1 (c), F2 (d), F3 (e) and F4 (f). 
 
In vitro buoyancy test 
Morphologically (Fig. 42), formulations F3 and F4, resulting from prilling of 
less viscous feed solutions, were the most porous. To investigate their ability 
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to float, buoyancy experiments were conducted through USP dissolution 
Apparatus II containing simulated gastric fluid – SGF and floating properties 
were determined by visual observation. As reported by Ishak (Ishak 2015), the 
time taken by beads to float on the medium surface was floating lag time 
(FLT). Particularly, F4 showed a significant floating ability as more than 75% 
of the particles float within 5 min of lag time (FLT) for all the duration of the 
experiment without disintegration (Fig. 45); on the contrary, F3 showed a 
delay in buoyancy (FLT of about 15 min) and only 25% of the beads float.  
 
Figure 45. Zn-ALG-ALM-Pct-HPMC beads loaded with PRX. In vitro floating images of 
formulation F4. 
 
Floating properties of F4 seem to be due to a combination of swelling of 
hydrocolloid particles with their low density, spongy and hollow inner 
structure. The hydration of the hydrocolloid beads surface in SGF results in an 
increased bulk volume and, at the same time, the presence of internal voids (as 
highlighted by SEM investigation) make beads able to entrap air acquiring 
bulk density less than 1, and, therefore, remaining buoyant on the acidic 
medium. Images obtained using transmitted (bright field) or in fluorescence 
(dark field) optical microscopy, were conducted on fractured particles 
withdrew from acidic medium. Microphotographs in figure 46 clearly 
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Fig.46. Zn-ALG-ALM-Pct-HPMC beads loaded with PRX .Microphotographs of hydrated 
fractured bead (F4) obtained using optical microscopy in bright-field (a-b) and fluorescent 
microscopy (c-d).  
In addition, the inner cross-linked multi-polysaccharide matrix may act as 
reservoir for slow and sustained PRX release controlled by a diffusion 
mechanism process through the swollen polymers gel layer (Singh and Kim 
2000). 
Drug release studies 
The hollow beads were tested to verify whether the porous ternary polymeric 
matrix is able to control and modulate PRX release in all gastrointestinal tract, 
by conventional dissolution test (Yang, Chu et al. 2002), using a standard pH 









Figure 47. Zn-ALG-ALM-Pct-HPMC beads loaded with PRX. PRX release profiles of 
formulations: a) F1 (-■-) and F2 (-●-), b) F3 (-▲-) and F4 (-■-), 
with respect to pure drug (-■-). 
 
F1-F4 showed a modulation of drug release especially in SGF at 120 min (30-
40%) compared to pure PRX (68.6% of drug release). Particularly F4, the 
formulation most spherical in shape and with spongy inner structure, showed 
an interesting bimodal pattern of release. During the permanence in acidic 
medium F4 released 44.5% of PRX, however, about 22% of NSAID was 
released in the first 30 min suggesting that F4 may provide a rapid onset of 
anti-inflammatory/analgesic action. In SIF, after pH-change, the release was 
very slower (52.8, 65.5, 80.2% PRX after 135, 150, 165 min) and the total 
drug liberation (98.5% ) was achieved at 270 min as compared to the rapid 
dissolving (82.4, 91 and 94.6% at the same time points) of the pure PRX. This 
sustained release of formulation F4 may keep the NSAID amount at the 




In vivo experiments 
To verify whether the bimodal and sustained release pattern in vitro of F4 may 
correspond to an extended anti-inflammatory action in vivo, the anti-
inflammatory effectiveness of floating formulation F4 was evaluated using a 
the model of carrageenan-induced oedema in rat paw as previously employed 
for other NSADs and SAIDs. Firstly, different doses of standard PRX were 
tested by administering the drug 0.5h before the carrageenan injection (Fig. 
48). The control group (ctr) received 1 ml of MC at the same time point before 
oedema induction. The dose of 1 mg kg
-1
 of PRX was selected as it achieved 
optimal anti-inflammatory effects (Fig. 48).  
 
 
Figure 48. Zn-ALG-ALM-Pct-HPMC beads loaded with PRX. Dose-response curve of 
pure PRX (0.1, 0.3, and 1 mg/kg doses) administered per os to rats 0.5 h before carrageenan 
injection; mean ± SEM (n = 8 per group). *p < 0.05, ***p ≤ 0.001 compared to control. 
 
To have evidence of potential prolonged in vivo anti-inflammatory activity of 
F4, as effect of its floating ability and sustained release properties, the 
multiple-units dosage form (PRX equivalent dose of 1 mg kg
-1
) was tested at 
different time points (3-5-24h up to 48h) before carrageenan injection in 
comparison to pure drug. Control groups received blank beads (F) or MC. 
Both F and MC did not affect the paw oedema in rats (data not shown). 
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F4 significantly reduced carrageenan-induced paw oedema as compared to 
control, when administered to rats 3h or 5h before carrageenan injection with 
an anti-inflammatory activity similar to pure PRX (1mg kg
-1
) (Fig. 49-A). But 
interestingly, F4 administered to rats 24h before oedema induction, showed a 
significant prolonged anti-inflammatory effect in terms of paw oedema 
inhibition whereas no response was observed for standard PRX. (Fig. 49-B). 
Additionally, F4 was still able to reduce the paw oedema in rats when 
administered up to 48h before the injection of the phlogistic agent (Fig 49-B). 
Results obtained indicated that floating and in vitro sustained release property 
of F4 is able to provide the dose fraction required to maintain an effective 
therapeutic plasma level of PRX for a prolonged period. In contrast, the 
standard drug (pure PRX 1mg kg
-1
), due to a more rapid release, was 





Figure 49. Zn-ALG-ALM-Pct-HPMC beads loaded with PRX. Oedema volume reduction 
obtained by administering F4 and pure PRX per os to rats 3-5h (A) and 24-48h (B) before 
carrageenan injection compared to control; mean ± SEM (n = 8). *p < 0.05, **p ≤ 0.01, ***p 
≤ 0.001 compared to control. 
 
4.2 Conclusions 
The present study suggests that prilling is a proper technique able to produce 
gastro-retentive (GR) delivery systems with floating ability and controlled 
drug release properties, using an appropriate multipolymer system based on 
natural and natural-derived polysaccharides (alginate, ALM-pectin and 
HMPC) with different key features, and without using any gas generating 
agent. The opportune set-up of process parameters and gelling conditions 
allows to produce interesting hollow gel-beads loaded with piroxicam which 





matrix. The final dosage form (F4) acts as a floating system in gastric medium 
able to control in vitro drug release and to extend in vivo the anti-inflammatory 
effectiveness of PRX up to 48h.  
The designed floating beads with bimodal and strictly controlled NSAID 
release pattern may give the possibility to overcome the fluctuations in plasma 
drug levels, providing both a loading and a maintenance dose of NSAIDs. 
Such beads may be proposed as carrier system for anti-inflammatory/analgesic 
drugs with biopharmaceutical and pharmacokinetic properties similar to PRX 
and when a bimodal (rapid plus sustained) drug release profile is required as in 





















MATERIALS & METHODS 
Materials  
Sodium alginate (European Pharmacopoeia 8, MW ≈ 240 KDa, 
mannuronic/guluronic ratio 1:2 viscosity 250-300 cP, 1% in H2O 20°C) 
employed as matrix in the preparation of gel-beads was used as purchased 
from Carlo Erba (Milan, Italy) without further purification. ALM-pectin 
(viscosity ~30 cP, 1% in H2O 20°C, MW ~ 150 KDa, esterification degree 
24% and amidation degree 23%) was kindly donated by Herbstreith & Fox 
KG (Neuenburg, Germany). Hydroxypropyl methylcellulose (HPMC_ 
viscosity 80-120 cP, 2% in H2O 20°C MW ~26 KDa), zinc acetate dehydrate 
(purity ≥ 99.0%) and calcium chloride (purity ≥ 93.0%) were supplied by 
Sigma- Aldrich (Sigma-Aldrich, Milan, Italy). 
Calcium carbonate (purity ≥ 99.0%) was acquired from J.T.Baker (Center 
Valley, USA). 
Ketoprofen and ketoprofen lysinate were kindly donated by Dompè (Dompè 
s.p.a. l’Aquila, Italy), whereas piroxicam was kindly donated by Sifavitor 
(Sifavitor srl, Milan, Italy). Prednisolone and all other chemicals and reagents 
were obtained from Sigma Aldrich (Milan, Italy) and used as supplied. 
Methods 
Drug loaded beads preparation 
Appropriate amounts of sodium alginate (2.0-2.25-2.5%) and ALM-pectin 
(6.00% w/w) or  together with HPMC (with total polymer concentration 
between 4.75% - 6.75% for piroxicam beads), were dissolved in distilled water 
at room temperature under gentle stirring for 18 hours in order to obtain 100 
ml of polymer solution. Various amounts of ketoprofen, ketoprofen lysinate, 
piroxicam or prednisolone were suspended into the polymer solution and 
stirred for 2 hours in order to obtain different drug/polymer ratios (1:20, 1:15, 
1:10, 1:5). Beads were manufactured by a vibrating nozzle device (Fig. 5, 
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Nisco Encapsulator Var D; Nisco Engineering Inc., Zurich, CH), equipped 
with a syringe pump (Model 200 Series, Kd Scientific Inc. Boston, MA, 
USA), pumping the drug/polymer solution through a nozzle 400 µm or 600 
µm in diameter. The experiments were performed at various volumetric flow 
rate, between 3 and 6 ml/min according to different formulations. The 
vibration frequency used to break up the laminar liquid jet was set between 
250 and 350 Hz, amplitude of vibration 100%. The distance between the 
vibrating nozzle and the gelling bath was fixed at 25 cm. A stroboscopic lamp 
was set at the same amplitude as the frequency, in order to visualize the falling 
droplets.  
Drug/polymer droplets fell into aqueous solutions (pH = 1.5) 0.5M or 10% 
w/v of calcium chloride or zinc acetate dehydrate or both of them 
simultaneously in different molar ratios (1:1, 1:4, 4:1), where they were gelled 
under gentle stirring. The beads were held into the gelling solution for 2-10 
minutes, (according to the different formulations), at room temperature or at 4-
5˚C (for ketoprofen lysinate beads), and then recovered and thoroughly rinsed 
with distilled water. As a comparison, unloaded beads (blank) were produced 
following the same protocol. The drying process of the hydrated beads was 
conducted by exposing them to standard room conditions (22 °C; 67% RH) for 
18–24 h until constant weight was reached. 
Core-shell beads preparation 
Regarding ALM-pectin-K beads, (Section A part 2) for the production of core-
shell systems the enteric coating solution was prepared by dissolving Eudragit 
S100
®
 in acetone at 6% (w/v) concentration. This solvent allowed complete 
dissolution of the enteric polymer while maintaining the integrity of beads. 
Coating was obtained by immersion of beads in the coating solution followed 
by solvent evaporation in a rotary evaporator. The process was repeated until 
the desired amount of coating was achieved. Microparticles were coated at 
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different levels (initial weight increase ranging from 10% to 60%). Samples of 
coated beads were then dried and weighed; the mean coating weight was 
calculated by difference with respect to the initial beads weight. 
Drug content and encapsulation efficiency 
 
Accurately weighed amounts of beads from each manufactured batch (about 
10 mg each) were dissolved under vigorous stirring in PBS buffer (100 mM 
pH 7.0) in order to disintegrate the polymer matrix and release the 
encapsulated drug. Afterwards, 23 ml of ethanol (or PBS for ketoprofen 
lysinate evaluation) were added and the suspension was centrifuged at 6000 
rpm for 15 min.  
The actual drug content (ADC) was determined by UV spectroscopy 
(Evolution 201 UV/VIS Spectrometer; Thermo Scientific, Waltham, MA) at λ 
254 nm (ketoprofen), λ 259 nm (ketoprofen lysinate), λ 244 (prednisolone) 
and λ 354 nm for piroxicam using the following equation: 
 
𝐴𝐷𝐶(%) =
𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑑𝑟𝑦 𝑏𝑒𝑎𝑑𝑠
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑦 𝑏𝑒𝑎𝑑𝑠 
× 100   Eq. 1 
 
Encapsulation efficiency was calculated as the ratio actual to theoretical drug 
content (TDC) i.e. the weight of drug added (g)/weight of polymers/excipients 
and drug added (g) x 100. Each analysis was performed in triplicate; results 
were expressed in terms of mean ± standard deviation.  
Beads size and morphology 
Scanning electron microscopy (SEM) was performed using a Carl Zeiss EVO 
MA 10 microscope with a secondary electron detector (Carl Zeiss SMT Ltd, 
Cambridge, UK) equipped with a LEICA EMSCD005 metallizator producing 




Projection diameter was obtained by image analysis (Image J software, Wayne 
Rasband, National Institute of Health, Bethesda, MD, USA). At least one 
hundred bead images were analysed for each preparation in order to calculate 
length-number mean and relative standard deviation for at least three different 
prilling processes.  
Perimeter and projection surface area obtained by image analysis were used to 
calculate a Sphericity Coefficient (SC) by the following equation (Almeida-







   (Eq.2) 
where A is the bead surface area and P its perimeter. 
Optical microscopy 
For ketoprofen loaded alginate beads (Section A part 1) and piroxicam loaded 
alginate-ALM pectin-HPMC beads (Section C) inner structure images were 
obtained by the cryo-fracture of the samples and further analysis by 
fluorescent microscopy (FM) through a Zeiss Axiophot microscope, equipped 
with a 20 × 1.4 NA and 10 × 0.3 no-oil immersion plan Apochromat objective 
(Carl Zeiss Vision, Munchen-Hallbergmoos, Germany) using standard 4,6-
diamidino-2-phenylindole optics that adsorb violet radiation (maximum 372 
nm) and emit a blue fluorescence (maximum 456 nm). In brief, freeze-fracture 
of the beads was performed by plunging the particles into liquid nitrogen for 1 
min, then fracturing the frozen beads by means of two needles. Split particles 
were attached to aluminium stab, covered with gold, and analysed. Other 
images reported in Section C were acquired from the same microscope using 
transmitted light microscopy (bright-field) equipped with a 2.5 × 0.3 and 10 × 





For prednisolone loaded alginate beads obtained with different cross-linkers 
(Section B part 1), the morphology and composition of the samples were 
inspected by scanning electron microscopy (SEM), model LEO EVO 50, 
equipped with energy dispersive spectrometer (EDS), model Oxford INCA 
Energy 300. Elemental maps were acquired for assessing the homogeneity of 
the samples composition. The EDS maps were performed by operating at 20 
KeV primary energy with a probe current of 100pA. 
Swelling behaviour 
For prednisolone loaded alginate beads (Section B, part 2), the swelling 
behaviour of the beads was evaluated by optical microscopy. A Leica inverted 
microscope equipped with a CCD camera (Leica, Milan, Italy) was employed. 
The beads were immersed in gastric simulated fluid for two hours and in 
intestinal simulated fluid until complete dissolution and observed at 
established time points. Swelling degree was determined as follow: 
 
%𝑠𝑤𝑒𝑙𝑙𝑖𝑛𝑔 =
𝑏𝑒𝑎𝑑 𝑠𝑖𝑧𝑒 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡−𝑏𝑒𝑎𝑑 𝑠𝑖𝑧𝑒 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑧𝑒𝑟𝑜
𝑏𝑒𝑎𝑑 𝑠𝑖𝑧𝑒 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑧𝑒𝑟𝑜
∙ 100  
Eq. 3 
 
All measurements were done in triplicate and the variability expressed as S.D. 
For beads examined in Section B part 1, swelling behaviour in the same 
simulated fluids, was evaluated. At pre-determined times, beads were 
withdrawn from the dissolution vessel, dabbed with paper to remove the water 
on the bead surface and then weighted. The swelling ratio (SR) for each 





𝑏𝑒𝑎𝑑 𝑤𝑒𝑖𝑔ℎ𝑡 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡−𝑏𝑒𝑎𝑑 𝑤𝑒𝑖𝑔ℎ𝑡 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑧𝑒𝑟𝑜
𝑏𝑒𝑎𝑑 𝑤𝑒𝑖𝑔ℎ𝑡 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑧𝑒𝑟𝑜
    Eq. 4 
 
Calorimetric analysis 
Beads thermal characteristics were determined by differential scanning 
calorimetry (DSC) (Mettler Toledo DSC 822e module controlled by Mettler 
Star E software, Columbus, OH, USA), and compared with those obtained 
using both blank beads and drugs raw materials. An appropriate amount of 
dried beads was crimped in a standard aluminium pan that was pierced and 
heated from 25 °C to 350 °C at a heating rate of 10 or 20 °C/min in nitrogen 
atmosphere at a flow rate of 150 ml/min. Characteristic peaks were recorded 
and specific heat of the melting endotherm was evaluated. 
Fourier Transform Infrared Spectroscopy (FT-IR) analyses 
For beads discussed in Section B part 2, FT-IR spectra were detected as KBr 
powder dispersion (Jasco model FT/IR-410, 420 Herschel series – Jasco 
Corporation Tokyo, Japan) using the EasiDiffTM Diffuse Reflectance 
Accessory. The samples were combined with small amount of potassium 
bromide and pressed to 6 tons in a manual press (OMCN s.p.a., Bergamo, 
Italy). The thin compacts produced were analysed using 256 scans and with a 
1 cm
−1 
resolution step. Each experiment was carried in triplicate and results 
averaged. 
In vitro buoyancy test 
Floating properties of prednisolone and piroxicam hollow beads (Section B 
part 3 and Section C) were measured in the USP dissolution Apparatus II 
(Sotax AT7 Smart – Sotax, Allschwil, CH) (Ishak 2015). A specific number of 
particles were placed in simulated gastric fluid – SGF (0.1 M hydrochloric 
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acid; pH 1; 75 rpm - 37°C) and the time required for the beads to rise to the 
surface of the medium and to float was considered as floating lag time (FLT). 
The percentage of floating or sinking particles was measured by visual 
observation (Ishak 2015) and determined after three experiments.  
Drug release studies 
In vitro dissolution/release tests were conducted in sink conditions on given 
amounts of bead formulations using a USP 27 dissolution apparatus II: paddle, 
100 rpm, 37°C (Sotax AT7 Smart – Sotax, Allschwil, CH) on line with a UV 
spectrophotometer (Lambda 25 UV/VIS Spectrometer, Perkin Elmer, 
Waltham, MA, USA).  
A classic pH-change assay, method A, according to <1092> monograph “The 
Dissolution Procedure: Development and Validation” (USP 36), was used. 
Briefly, dried beads were added to the dissolution medium, 750 ml 0.1M HCl 
(SGF) for 2 h, then 250 ml of 0.2M Na3PO4 was added and pH adjusted to 6.8 
(SIF). While for floating beads the dissolution experiments were conducted 
only in SGF for all the duration of the experiment. 
Data were analysed spectrophotometrically at λ 258 nm (SGF) and λ 260 nm 
(SIF) for ketoprofen, λ 259 nm for ketoprofen lysinate, λ 244 nm for 
prednisolone, whereas piroxicam was analysed at λ 333 and λ 354 nm, for 
gastric and intestinal simulated environment, respectively.  
Ketoprofen lysinate and prednisolone optimized formulations (Section A part 
3 and Section B part 2) were introduced into selected capsules (DR® caps) and 
their release from these dosage forms was evaluated using the USP-II 
apparatus equipped with mesh basket (USP Standard Size Mesh, 40) and the 
experimental protocol previously reported. 
Dissolution tests were conducted on six different batches of particles; mean 




Kinetic of drug release 
In order to evaluate prednisolone diffusion coefficient when released through 
the different crosslinked alginate matrix (Section B part 1), the analysis of 
released amount of the drug was performed, splitting the release into two 
phases corresponding to gastric and intestinal environments. Two common 
kinetic models were used to fit the release data. The Higuchi's model (Eq. (5)) 
that is the most used to investigate pure Fickian transport: 
  
𝑀𝑡 = 𝐴√𝐷(2𝐶0 − 𝐶𝑆)𝑡  (5) 
 
where Mt is the drug cumulative amount released at time t, t is time, A is the 
surface area, D the diffusivity of the drug through the matrix, and C0 and Cs 
are the initial drug concentration and drug solubility, respectively. This model 
is applicable when drug solubility is higher than drug concentration, and when 
pure diffusion is the leading release mechanism (Higuchi 1961). The second 




= 𝑘𝑡𝑛 (6) 
where M∞ is the drug amount released at infinity, k is a constant, and n is a 
diffusion coefficient, which depends on geometry and release mechanism of 
the formulation (Ritger and Peppas 1987). 
Since Eq. 5 and 6 are usually limited to the description of the first 60% of 
release whereas in the study we compared the fitting performed over 60% of 
release to that over 100% of the profile to address adequacy of the procedure 
employed, Levenberg–Marquardt method was applied in order to evaluate the 
lack of fit correlation coefficient normalized to the degree of freedom of the 
system (Marquardt 1963; Del Gaudio, De Cicco et al. 2015). 
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Animals and carrageenan oedema induction 
Male Wistar rats (180-220g) were purchased from Charles River (Charles 
River Laboratories, Calco, Italy). Rats were anaesthetized with isoflurane and 
oedema was induced by injecting in the right hind paw 100µl of carrageenan 
1% (w/v) as previously reported (Cicala, Morello et al. 2007). Paw volume 
(ml) was measured plethysmographycally (2Biological-Instruments, Italy) at 
the time zero, each hour for 6h, and at 24h after carrageenan injection. Data 
were expressed as mean ± S.E.M. Statistical differences were evaluated by 
two-way analysis of variance (ANOVA). P value of <0.05 was considered 
statistically significant. All the experiments were approved by Italian Health 
Ministry (authorization n° 805/2015-PR) and conducted according to 
institutional animal care guidelines, Italian Law 26/2014 based on the 
European Community Law for Animal Care 2010/63/UE. 
In vivo experiments  
Dose-response curves of standard ketoprofen (K) and prednisolone (P) (dose 
per os 1.0, 3.0 and 10.0 mg/kg) or piroxicam (dose per os 0.1, 0.3 and 1 
mg/kg) were performed by oral administration of the drug to rats 0.5h before 
the carrageenan injection, using an aqueous solution of methylcellulose, MC 
(0.5% w/v) as vehicle (Chakraborty, Khandai et al. 2010).  
To assess the in vivo anti-inflammatory effectiveness of best formulations in 
comparison with the reference drugs, rats were treated by oral gavage with the 
formulations (K and P equivalent dose 3 mg kg
-1
; PRX equivalent dose 1 mg 
kg
-1
) or raw with reference K, P, PRX in 0.5% (w/v) methyl cellulose 
(Chakraborty, Khandai et al. 2010) using the same doses. Samples were 
administered to rats at different times before the injection of the phlogistic 
agent accordingly with formulation type (0.5, 3, 5, 15, 24, 48h). Control 
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